

University of Groningen

Encyclopaedia of tumour-associated familial disorders. Part I

Sijmons, Rolf H.

Published in:
Hereditary cancer in clinical practice

DOI:
[10.1186/1897-4287-6-1-22](https://doi.org/10.1186/1897-4287-6-1-22)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2008

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Sijmons, R. H. (2008). Encyclopaedia of tumour-associated familial disorders. Part I: from AIMA to CHIME syndrome. *Hereditary cancer in clinical practice*, 6(1), 22-57. [22]. <https://doi.org/10.1186/1897-4287-6-1-22>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Encyclopaedia of tumour-associated familial disorders.

Part I: from AIMAH to CHIME syndrome

Rolf H. Sijmons

Department of Genetics, University Medical Center, University of Groningen, Groningen, The Netherlands

Key words: familial cancer, tumour syndromes, database, genes, review

Corresponding author: Rolf H. Sijmons, MD, PhD, Department of Genetics, University Medical Center, Groningen, University of Groningen, PO Box 30001, 9700 RB, Groningen, The Netherlands, phone: +31 50 361 71 00, fax: +31 50 361 72 30, e-mail: r.h.sijmons@medgen.umcg.nl

Submitted: 11 February 2008

Accepted: 12 February 2008

Abstract

Cancer is associated with a wide range of hereditary disorders. Recognizing these disorders in cancer patients may be of great importance for the medical management of both patients and their relatives. Conversely, recognizing the fact that cancer may develop as a complication of a particular hereditary disorder which has already been diagnosed may be important for the same reason. The Familial Cancer Database (FaCD) is a web-based application (www.facd.info) which has been developed at our department with the intention to assist clinicians and genetic counsellors in making a genetic differential diagnosis in cancer patients, as well as in becoming aware of the tumour spectrum associated with hereditary disorders that have already been diagnosed in their patients. This encyclopaedia is published in parts and discusses the disorders included in the FaCD database in alphabetical order. It lists names, synonyms, OMIM number, mode of inheritance, associated genes, phenotype, clinical discussion and references. The purpose of presenting this encyclopaedia in paper format is simply that we hope that you as clinicians and researchers find it helpful to browse through it and familiarize yourself even better with the scope of genetic disorders that have been associated with increased tumour risk.

Introduction

Cancer is associated with a wide range of hereditary disorders. Recognizing these disorders in cancer patients may be of great importance for the medical management of both patients and their relatives. Conversely, recognizing the fact that cancer may develop as a complication of a particular hereditary disorder which has already been diagnosed may be important for the same reason. The Familial Cancer Database (FaCD) is a web-based application (www.facd.info) which has been developed at the Department of Genetics of

the University Medical Center Groningen, The Netherlands, with the intention to assist clinicians and genetic counsellors in making a genetic differential diagnosis in cancer patients, as well as in becoming aware of the tumour spectrum associated with hereditary disorders that have already been diagnosed in their patients. This encyclopaedia is published in parts and discusses the disorders included in the FaCD database in alphabetical order. It lists names, synonyms, genes involved, phenotype, brief clinical discussion and references. The following classes of disorders have been included in this paper: hereditary disorders certainly or

possibly associated with increased cancer risk (e.g. Lynch syndrome) and familial clustering of particular types of cancer *e.c.i.* (for example familial occurrence of salivary gland tumours). If some fields are not listed for a particular disorder, for example 'Non-tumour features', then those fields are empty for that disorder. Especially in rare syndromes it can be difficult to decide whether or not a particular tumour type truly belongs to the phenotype of that disorder. Those tumours have been classified below as '*Tumour features (possible)*' in the descriptions of the phenotypes. The purpose of presenting this encyclopaedia in paper format is that we hope that you as clinicians and researchers find it helpful to browse through it and familiarize yourself even better with the scope of genetic disorders that have been associated with increased tumour risk.

Abbreviations used:

AD – autosomal dominant
 AR – autosomal recessive
 CGD – contiguous gene deletion
 CI – confidence interval
 de novo – de novo mutation
 Impr – subject to genomic imprinting
 Multifactorial – multifactorial inheritance
 OMIM number – the number of the disorder in Online Mendelian Inheritance in Men
 Pat – paternal
 RR – relative risk
 SIR – standardized incidence ratio
 Upd – uniparental disomy
 XLR or XLD – X-linked recessive or dominant, respectively
 ? – reflects uncertainty with respect to mode of inheritance

ACTH-independent macronodular adrenal hyperplasia

Synonym: AIMAH, Cushing's disease, adrenal, familial

Mode of inheritance: spor/AD

OMIM number: 219080

Genes:

GNAS1, mapped to 20q13.2

Tumour features:

macronodular adrenal hyperplasia

Non-tumour features:

adrenal dysplasia
 adrenal hyperplasia

Comment

AIMAH cases are usually sporadic, causing Cushing's disease generally in the 5th or 6th decade.

Affected siblings with Cushing's disease caused by primary (ACTH independent) adrenal, often bilateral, nodular hyperplasia and dysplasia have been observed [1-5]. Somatic GNAS1 mutations have been observed in isolated AIMAH cases.

References

1. Christopoulos S, Bourdeau I, Lacroix A. Clinical and subclinical ACTH-independent macronodular adrenal hyperplasia and aberrant hormone receptors. *Horm Res* 2005; 64: 119-131.
2. Donaldson MD, Grant DB, O'Hare MJ, Shackleton CH. Familial congenital Cushing's syndrome due to bilateral nodular adrenal hyperplasia. *Clin Endocrinol (Oxf)* 1981; 14: 519-526.
3. Hodge BO, Froesch TA. Familial Cushing's syndrome. Micronodular adrenocortical dysplasia. *Arch Intern Med* 1988; 148: 1133-1136.
4. Findlay JC, Sheeler LR, Engeland WC, Aron DC. Familial adrenocorticotropin-independent Cushing's syndrome with bilateral macronodular adrenal hyperplasia. *J Clin Endocrinol Metab* 1993; 76: 189-191.
5. Teding van Berkhout F, Croughs RJ, Wulffraat NM, Drexhage HA. Familial Cushing's syndrome due to nodular adrenocortical dysplasia is an inherited disease of immunological origin. *Clin Endocrinol (Oxf)* 1989; 31: 185-191.

Acute lymphoblastic leukaemia, familial clustering of

Synonym: familial ALL, including familial T-ALL

Mode of inheritance: AD?/multifactor?

Genes:

CYP1A1, mapped to 15q22-q24

GSTM1, mapped to 1p13.3

HLA-DQB1, mapped to 6p21.3

Tumour features:

leukaemia, acute lymphoblastic (ALL)

Comment

Familial clustering of ALL has been observed [1-3]. Becker et al. [4] reported a 4-generation Irish family with childhood onset acute T-cell leukaemia/lymphoblastic T-cell lymphoma in 9 relatives, which to the authors suggested autosomal dominant inheritance with reduced penetrance.

Dearden et al. [5] studied HLA-DQB1 alleles in children with ALL because of the suggestion that ALL may be caused by HLA-regulated susceptibility to an unidentified neonatal infection. They observed a significant excess of the DQB1*05 allele (RR 2.5) and in particular of certain amino acid motifs (not restricted to that allele). Polymorphisms in the GSTM1 and CYP1A1 genes, encoding xenobiotic-metabolizing enzymes, have been found to be associated with an

increased relative risk of childhood ALL [6]. A germline heterozygous truncating mutation in the gene for Fanconi anaemia type C has been detected in 2 sibs with T-ALL; 1 of the sibs subsequently developed AML [7]. In general, there appears to be no increase in ALL risk to siblings of patients. Risk may even be decreased and it has been speculated that immunization of mothers to leukaemia-specific antigens may occur which can enhance elimination of pre-leukaemic cells in utero [8].

References

1. Kende G, Toren A, Mandel M, Neumann Y, Kenet G, Brok-Simoni F, Ramot B, Ben-Bassat I, Rechavi G. Familial leukemia: description of two kindreds and a review of the genetic aspects of the disease. *Acta Haematol* 1994; 92: 208-211.
2. Cramblett HG, Friedman JL, Najjar S. Leukemia in an infant born of a mother with leukemia. *N Engl J Med* 1958; 259: 727-729.
3. Chaganti RS, Miller DR, Meyers PA, German J. Cytogenetic evidence of the intrauterine origin of acute leukemia in monozygotic twins. *N Engl J Med* 1979; 300: 1032-1034.
4. Becker K, Breatnach F, Green AJ. Autosomal dominant acute T-cell leukemia/lymphoblastic T-cell lymphoma in an Irish family. *J Med Genet* 2000; 37 (Suppl 1): S35.
5. Dearden SP, Taylor GM, Gokhale DA, Robinson MD, Thompson W, Ollier W, Binchy A, Birch JM, Stevens RF, Carr T, Bardsley WG. Molecular analysis of HLA-DQB1 alleles in childhood common acute lymphoblastic leukaemia. *Br J Cancer* 1996; 73: 603-609.
6. Krajcinovic M, Labuda D, Richer C, Karimi S, Sinnett D. Susceptibility to childhood acute lymphoblastic leukemia: Influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. *Blood* 1999; 93: 1496-1501.
7. Rischewski JR, Clausen H, Leber V, Niemeyer C, Ritter J, Schindler D, Schneppenheim R. A heterozygous frameshift mutation in the Fanconi anemia C gene in familial T-ALL and secondary malignancy. *Klin Padiatr* 2000; 212: 174-176.
8. Schmiegelow K, Hjalgrim H. Is the risk of acute lymphoblastic leukemia reduced in siblings to children with the disease? A novel hypothesis explored by international collaboration. *Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K.* 2006; 20: 1206-1208.

Acute myelocytic leukaemia with polyposis coli and colon cancer

Mode of inheritance: AR?

OMIM number: 246470

Tumour features:

bladder polyps

colorectal cancer

leukaemia, acute myeloblastic (AML, M2)

Comment

Two brothers with consanguineous parents were reported by Greenberg et al. [1] to have developed multiple colorectal adenomatous polyps, early-onset colorectal cancer, acute myeloblastic leukaemia, and (in one of the brothers) papillary bladder tumours. This could have been a case of bi-allelic MMR gene mutations.

References

1. Greenberg MS, Anderson KC, Marchetto DJ, Li FP. Acute myelocytic leukemia in two brothers with polyposis coli and carcinoma of the colon. *Ann Intern Med* 1981; 95: 702-703.

Adenosine deaminase deficiency

Synonym: severe combined immunodeficiency (SCID) due to ADA deficiency

Mode of inheritance: AR

OMIM number: 102700

Genes:

ADA, mapped to 20q13.11

Tumour features:

Burkitt's lymphoma

Hodgkin's disease

leukaemia, acute

non-Hodgkin's lymphoma

Non-tumour features:

adenosine deaminase deficiency

agammaglobulinaemia

immunodeficiency

skeletal dysplasia

Comment

A substantial percentage of (apparently) autosomal recessive severe combined immunodeficiency is caused by deficiency of adenosine deaminase. Dysplastic skeletal changes (typically of costochondral junctions) occur frequently in patients with ADA deficiency. Most cases are diagnosed in the first year [1]. As in other types of severe combined immune deficiency, there is an increased risk of developing malignancies of the haemato-lymphoproliferative type [2-5]. There appears to be no increased cancer risk for heterozygotes of the mutant gene [6].

References

1. Hershfield MS. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. *Semin Hematol* 1998; 35: 291-298.
2. Filipovich AH, Spector BD, Kersey J. Immunodeficiency in humans as a risk factor in the development of malignancy. *Prev Med* 1980; 9: 252-259.

3. Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency diseases. A literature review. *Cancer* 1971; 28: 89-98.
4. Husain M, Grunebaum E, Naqvi A, Atkinson A, Ngan BY, Aiuti A, Roifman CM. Burkitt's lymphoma in a patient with adenosine deaminase deficiency-severe combined immunodeficiency treated with polyethylene glycol-adenosine deaminase. *J Pediatr* 2007; 151: 93-95.
5. Kaufman DA, Hershfield MS, Bocchini JA, Moissidis IJ, Jeroudi M, Bahna SL. Cerebral lymphoma in an adenosine deaminase-deficient patient with severe combined immunodeficiency receiving polyethylene glycol-conjugated adenosine deaminase. *Pediatrics* 2005; 116: e876-e879.
6. Morrell D, Chase CL, Swift M. Cancer in families with severe combined immune deficiency. *J Natl Cancer Inst* 1987; 78: 455-458.

Agammaglobulinaemia, X-linked

Synonym: Bruton type agammaglobulinaemia

Mode of inheritance: XLR

OMIM number: 300300, 300310

Genes:

BTK, mapped to Xq21.3-q22

Tumour features:

colorectal cancer

Hodgkin's disease

leukaemia, acute lymphoblastic (ALL)

leukaemia, chronic myeloid (CML)

non-Hodgkin's lymphoma

thymoma

Tumour features (possible):

gastric cancer

lung/bronchial cancer

Non-tumour features:

agammaglobulinaemia

immunodeficiency

2. Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency diseases. A literature review. *Cancer* 1971; 28: 89-98.
3. van der Meer JW, Zegers BJ. Agammaglobulinaemia. *Neth J Med* 1994; 45: 250-256.
4. Filipovich AH, Spector BD, Kersey J. Immunodeficiency in humans as a risk factor in the development of malignancy. *Prev Med* 1980; 9: 252-259.
5. Lederman HM. Cancer in children with primary or secondary immunodeficiencies. *J Pediatr* 1995; 127: 335.
6. Page AR, Hansen AE, Good RA. Occurrence of leukemia and lymphoma in patients with agammaglobulinemia. *Blood* 1963; 21: 197-206.
7. Mueller BU, Pizzo PA. Cancer in children with primary or secondary immunodeficiencies. *J Pediatr* 1995; 126: 1-10.
8. Spector BD, Perry GS 3rd, Kersey JH. Genetically determined immunodeficiency diseases (GDID) and malignancy: report from the immunodeficiency-cancer registry. *Clin Immunol Immunopathol* 1978; 11: 12-29.
9. Kersey JH, Spector BD, Good RA. Primary immunodeficiency diseases and cancer: the immunodeficiency-cancer registry. *Int J Cancer* 1973; 12: 333-347.
10. van der Meer JW, Weening RS, Schellekens PT, van Munster IP, Nagengast FM. Colorectal cancer in patients with X-linked agammaglobulinaemia. *Lancet* 1993; 341: 1439-1440.
11. Brosens LA, Tytgat KM, Morsink FH, Sinke RJ, Ten Berge IJ, Giardiello FM, Offerhaus GJ, Keller JJ. Multiple colorectal neoplasms in X-linked agammaglobulinemia. *Clin Gastroenterol Hepatol* 2008; 6: 115-119.
12. Echave-Sustaeta JM, Villena V, Verdugo M, López-Encuentra A, de Agustín P, Alberti N. X-linked agammaglobulinaemia and squamous lung cancer. *Eur Respir J* 2001; 17: 570-572.
13. Bachmeyer C, Monge M, Cazier A, Le Deist F, de Saint Basile G, Durandy A, Fischer A, Mougeot-Martin M. Gastric adenocarcinoma in a patient with X-linked agammaglobulinaemia. *Eur J Gastroenterol Hepatol* 2000; 12: 1033-1035.
14. Lavilla P, Gil A, Rodríguez MC, Dupla ML, Pintado V, Fontán G. X-linked agammaglobulinemia and gastric adenocarcinoma. *Cancer* 1993; 72: 1528-1531.

Comment

This infantile immunodeficiency in males is characterized by an isolated B-cell defect and these cells are absent in the vast majority of patients. Lymphoid tissue (adenoid, tonsils) is either absent or hypoplastic. There is approximately an incidence of 1.5-6% of malignancies in this disorder, mainly involving the haematopoietic-lymphoid system [1-9]. Patients also have an increased risk of developing colorectal cancer [10,11]. Lung cancer was diagnosed in a 32-year-old non-smoking male with the disorder [12]. Gastric cancer associated with chronic atrophic gastritis [13, 14].

References

1. Penn I. Occurrence of cancer in immune deficiencies. *Cancer* 1974; 34 (Suppl): 858-866.

Aicardi syndrome

Mode of inheritance: XLD

OMIM number: 304050

Genes:

AIC, mapped to Xp22

Tumour features (possible):

angiosarcoma

choroid plexus papilloma

colorectal polyps

gastric polyps

hepatoblastoma

lipoma

medulloblastoma

palate, benign teratoma of

parapharyngeal embryonal cell cancer

Non-tumour features:

chorioretinal lacunae
cleft lip
cleft palate
corpus callosum agenesis
facies, asymmetric
gross motor delay
mental deficiency
plagiocephaly
rib anomalies
seizures
vertebral anomalies

Comment

Clinical hallmarks are infantile spasms, corpus callosal agenesis, chorioretinal abnormalities (lacunae) and severe psychomotor retardation. Other findings include plagiocephaly, facial asymmetry, cleft lip and palate and costovertebral anomalies. A number of tumours have been reported in association with Aicardi syndrome [1-7]: choroid plexus papilloma (the most frequent tumour), medulloblastoma, gastric hyperplastic polyps, rectal polyps, soft palate benign teratoma, hepatoblastoma, parapharyngeal embryonal cell cancer, limb angiosarcoma and scalp lipoma.

References

1. Trifiletti RR, Incorpora G, Polizzi A, Cocuzza MD, Bolan EA, Parano E. Aicardi syndrome with multiple tumors: a case report with literature review. *Brain Dev* 1995; 17: 283-285.
2. Tagawa T, Mimaki T, Ono J, Tanaka J, Imai K, Yabuuchi H. Aicardi syndrome associated with an embryonal carcinoma. *Pediatr Neurol* 1989; 5: 45-47.
3. Tsao CY, Sommer A, Hamoudi AB. Aicardi syndrome, metastatic angiosarcoma of the leg, and scalp lipoma. *Am J Med Genet* 1993; 45: 594-596.
4. Tanaka T, Takakura H, Takashima S, Kodama T, Hasegawa H. A rare case of Aicardi syndrome with severe brain malformation and hepatoblastoma. *Brain Dev* 1985; 7: 507-512.
5. Robinow M, Johnson GF, Minella PA. Aicardi syndrome, papilloma of the choroid plexus, cleft lip, and cleft of the posterior palate. *J Pediatr* 1984; 104: 404-405.
6. Frye RE, Polling JS, Ma LC. Choroid plexus papilloma expansion over 7 years in Aicardi syndrome. *J Child Neurology* 2007; 22: 484-487.
7. Palmér L, Nordborg C, Steneryd K, Aman P, Kyllerman M. Large-cell medulloblastoma in Aicardi syndrome. Case report and literature review. *Neuropediatrics* 2004; 35: 307-311.

Alagille syndrome

Synonym: ALGS1, ALGS2, Alagille-Watson syndrome

Mode of inheritance: AD/AR?

OMIM number: 118450

Genes:

JAG1, mapped to 20p12

NOTCH2, mapped to 1p13-p11

Tumour features:

hepatocellular cancer

Tumour features (possible):

thyroid cancer, papillary

Wilms' tumour (nephroblastoma)

Non-tumour features:

bile ducts, paucity of intrahepatic

chin, triangular

embryotoxon posterior

eyes, deeply set

frontal bossing/prominent forehead

hypertelorism

midface, flat/hypoplastic

nose, long straight

philtrum, short

pulmonary artery stenosis

vertebral anomalies

Comment

Hallmarks of this disorder are: paucity of intrahepatic bile ducts leading to cholestasis, peripheral pulmonary artery stenosis, vertebral arch defects, poor linear growth, a characteristic facies and embryotoxon posterior in the eye [1]. Hepatocellular cancer has been reported in a number of cases [2-5], and papillary thyroid cancer [6] and Wilms' tumour in one case [7].

References

1. Deleuze JF, Dhorne-Pollet S, Pollet N, Meunier-Rotival M, Hadchouel M. Alagille syndrome in 1995. Clinical and genetical data. *Gastroenterol Clin Biol* 1995; 19: 587-596.
2. Kaufman SS, Wood RP, Shaw BW Jr, Markin RS, Gridelli B, Vanderhoof JA. Hepatocarcinoma in a child with the Alagille syndrome. *Am J Dis Child* 1987; 141: 698-700.
3. Ong E, Williams SM, Anderson JC, Kaplan PA. MR imaging of a hepatoma associated with Alagille syndrome. *J Comput Assist Tomogr* 1986; 10: 1047-1049.
4. Le Bail B, Bioulac-Sage P, Arnoux R, Perissat J, Saric J, Balabaud C. Late recurrence of a hepatocellular carcinoma in a patient with incomplete Alagille syndrome. *Gastroenterology* 1990; 99: 1514-1516.
5. Kim B, Park SH, Yang HR, Seo JK, Kim WS, Chi JG. Hepatocellular carcinoma occurring in alagille syndrome. *Pathol Res Pract* 2005; 201: 55-60.

6. Kato Z, Asano J, Kato T, Yamaguchi S, Kondo N, Orii T. Thyroid cancer in a case with the Alagille syndrome. *Clin Genet* 1994; 45: 21-24.
7. Bourdeaut F, Guiochon-Mantel A, Fabre M, Martelli H, Patte C, Porta G, Bernard O, Delattre O, Jacquemin E. Alagille syndrome and nephroblastoma: Unusual coincidence of two rare disorders. *Pediatr Blood Cancer*. E-head print.

Alpha-1-antitrypsin deficiency

Mode of inheritance: AD

OMIM number: 107400

Genes:

PI, mapped to 14q32.1

Tumour features:

hepatocellular cancer

Tumour features (possible):

colorectal cancer

lung/bronchial cancer

Non-tumour features:

liver cirrhosis

lung emphysema

Comment

This disorder is caused by deficiency of alpha-1-antitrypsin (= protease inhibitor = anti-elastase) and is characterized by emphysema and juvenile or adult liver cirrhosis. The severity of the disease depends on the specific combination of alleles and very likely also on the influence of exogenous factors such as smoking. The homozygous null allele combination causes the most severe disease, followed by the ZZ combination. Risk of hepatocellular cancer is increased, possibly only in males [1, 2] and depending on allele type [3]. It has been reported in children [4]. Alpha-1-antitrypsin deficiency/haplosufficiency may also act as a co-risk factor for lung cancer [5]. Yang et al. [6] estimated a 20-fold increase in risk of developing colorectal cancer (with microsatellite instability, MSI-H) among smokers who carry alpha-1-antitrypsin deficiency alleles.

References

1. Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha1-antitrypsin deficiency. *N Engl J Med* 1986; 314: 736-739.
2. Rudnick DA, Perlmuter DH. Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. *Hepatology* 2005; 42: 514-521.
3. Fargion S, Klasen EC, Lalatta F, Sangalli G, Tommasini M, Fiorelli G. Alpha1-antitrypsin in patients with hepatocellular carcinoma and chronic active hepatitis. *Clin Genet* 1981; 19: 134-139.
4. Hadzic N, Quaglia A, Mieli-Vergani G. Hepatocellular carcinoma in a 12-year-old child with PiZZ alpha1-antitrypsin deficiency. *Hepatology* 2006; 43: 194.

5. Wentzlaff K, Marks R, Knutson A, Tazelaar H, Lindor N, Yang P. Family history of lung cancer patients who are alpha1-antitrypsin deficiency carriers. *Am J Hum Genet* 1998; 63 (Suppl): A100.
6. Yang P, Cunningham J, Katzmann J, Lesnick T, Halling K, Bugart L, Wiegert E, Christensen E, Kyle R, Lindor N, Thibodeau S. A 20-fold increase in risk of colorectal cancer with defective mismatch repair among current smokers who carry alpha-1 antitrypsin deficiency alleles. *Am J Hum Genet* 1999; 65: A40.

Alpha-fetoprotein, hereditary persistence of

Synonym: HPAFP

Mode of inheritance: AD

OMIM number: 104150

Genes:

AFP, mapped to 4q11-q13

Tumour features (possible):

non-seminoma

seminoma

Non-tumour features:

increased/persistent serum AFP

Comment

This disorder is characterized by the persistence of high AFP, due to a mutation in the AFP gene [1, 2]. Staples et al. [3] reported high serum AFP in a 23-year-old man with a testicular seminoma as well as in his 3 sisters, mother and maternal aunt. He also had hereditary spherocytosis. Hart et al. [4] and Cochran et al. [5] reported a yolk sac tumour in a 20-year-old male and a 20-month-old male with HPAFP, respectively. Although the association is probably purely coincidental, it is important to stress that HPAFP may confuse management in patients with testicular or liver tumours, or other conditions where AFP levels are of diagnostic or screening importance. If HPAFP is not recognized in these conditions, then this may lead to inappropriate medical decisions. Testing parental levels of AFP has been advised for cases where persistent (mild) elevation of AFP following resection of localized germ cell tumours has been observed, before deciding on chemotherapy [5].

References

1. McVey JH, Michaelides K, Hansen LP, Ferguson-Smith M, Tilghman S, Krumlauf R, Tuddenham EG. AG→A substitution in an HNF I binding site in the human alpha- fetoprotein gene is associated with hereditary persistence of alpha-fetoprotein (HPAFP). *Hum Mol Genet* 1993; 2: 379-384.
2. Schefer H, Mattmann S, Joss RA. Hereditary persistence of alpha-fetoprotein. Case report and review of the literature. *Ann Oncol* 1998; 9: 667-672.
3. Staples J. Alphafetoprotein, cancer, and benign conditions. *Lancet* 1986; 2: 1277.

4. Hart PS, Nanton JR, Vlasovich AC, Berry MN, Chauvenet A. Hereditary persistence of alpha-fetoprotein and testicular cancer in a 20 month old male. *Am J Hum Genet* 1997; 61: A68.
5. Cochran PK, Chauvenet AR, Hart PS, de Graaf SS, Cushing B, Kroovand L, Wofford MM. Misleading leads. Hereditary persistence of alpha-fetoprotein in a child with testicular germ cell tumor. *Med Pediatr Oncol* 1999; 32: 436-437.

Alport syndrome with diffuse leiomyomatosis

Mode of inheritance: XLD/cgd

OMIM number: 308940

Genes:

COL4A5, mapped to Xq22-q24

COL4A6, mapped to Xq22-q24

Tumour features:

bronchioli, leiomyoma of the

oesophageal leiomyoma

gastric leiomyoma

leiomyoma of the clitoris

leiomyoma of the urethra

trachea, leiomyoma of the

uterine leiomyoma

vulvar leiomyoma

Non-tumour features:

cataract, congenital

deafness, neurosensory

nephropathy

Comment

Alport syndrome is characterized by haematuric nephropathy, in most cases leading to renal failure (usually progressive), sensorineural deafness and ocular anomalies (maculopathy and anterior lenticonus). Some patients with Alport syndrome develop diffuse leiomyomatosis (especially of the oesophagus and less often the vulva and other anatomical sites). These patients also frequently have severe cataracts. The oesophageal leiomyomas appear to develop earlier among boys (average age 6 years compared to 14 years in girls) [1-4].

Alport syndrome is genetically heterogeneous. The specific subset of patients/families with Alport syndrome and leiomyomatosis is associated with deletions extending from within the COL4A5 gene to the neighbouring COL4A6 gene [5, 6]. Multiple giant gastro-oesophageal leiomas have been reported in the absence of such a detectable deletion [7].

References

1. Garcia-Torres R, Orozco L. Alport-leiomyomatosis syndrome: an update. *Am J Kidney Dis* 1993; 22: 641-648.

2. Zhou J, Mochizuki T, Smeets H, Antignac C, Laurila P, de Paepe A, Tryggvason K, Reeders ST. Deletion of the paired alpha 5(IV) and alpha 6(IV) collagen genes in inherited smooth muscle tumors. *Science* 1993; 261: 1167-1169.
3. Antignac C, Heidet L. Mutations in Alport syndrome associated with diffuse esophageal leiomyomatosis. *Contrib Nephrol* 1996; 117: 172-182.
4. Anker MC, Arnemann J, Neumann K, Ahrens P, Schmidt H, König R. Alport syndrome with diffuse leiomyomatosis. *Am J Med Genet A* 2003; 119: 381-385.
5. Garcia-Torres R, Cruz D, Orozco L, Heidet L, Gubler MC. Alport syndrome and diffuse leiomyomatosis. Clinical aspects, pathology, molecular biology and extracellular matrix studies. A synthesis. *Nephrologie* 2000; 21: 9-12.
6. Thielen BK, Barker DF, Nelson RD, Zhou J, Kren SM, Segal Y. Deletion mapping in Alport syndrome and Alport syndrome-diffuse leiomyomatosis reveals potential mechanisms of visceral smooth muscle overgrowth. *Hum Mutat* 2003; 22: 419.
7. Prenzel KL, Schäfer E, Stippel D, Beckurts KT, Hölscher AH. Multiple giant leiomyomas of the esophagus and stomach. *Dis Esophagus* 2006; 19: 504-508.

Amenorrhoea-galactorrhoea syndrome

Mode of inheritance: AD?

OMIM number: 104600

Tumour features:

pituitary adenoma

Comment

Familial cases of galactorrhoea and amenorrhoea, due to a pituitary gland tumour, have been reported [1, 2]. Possibly these cases represent in fact multiple endocrine neoplasia type 1 or another type of hereditary pituitary gland tumours.

References

1. Linquette M, Herlant M, Laine E, Fossati P, Dupont-Lecompte M. Adenome a prolactine chez une fille dont la mere etait porteuse d'un adenome hypophysaire avec amenorrhee-galactorrhee. *Ann Endocrinol* 1967; 28: 773-780.
2. Young RL, Bradley EM, Goldzieher JW, Myers PW, Lecocq FR. Spectrum of nonpuerperal galactorrhea: report of two cases evolving through the various syndromes. *J Clin Endocrinol Metab* 1967; 27: 461-466.

Androgen insensitivity syndrome

Synonym: AIS, testicular feminisation, Reifenstein syndrome

Mode of inheritance: X-linked

OMIM number: 300068

Genes:

AR, mapped to Xq11-q12

Tumour features:

non-seminoma

seminoma

testicular gonadoblastoma

testicular Sertoli-Leydig cell tumour

Non-tumour features:

male (46,XY) pseudohermaphroditism

Comment

Mutations in the androgen receptor coding gene on the X chromosome cause pseudo-hermaphroditism in the XY individual through androgen insensitivity. External genitals are female. The gonads are undescended testes and may be intra-abdominal, inguinal, or labial. Mullerian structures (including uterus) are absent, because of AMH production by the testicles [1].

Sex cord hamartomas and Sertoli cell adenomas are common findings in AIS, with a prevalence of 63 and 23%, respectively, observed in one series of 43 patients [2]. Patients with AIS show an increased frequency of testicular malignancies with risks estimated between 2 and 33%; 2-10% might be the most realistic estimate. Seminoma [3-8] and sex-cord stromal tumours (particularly Sertoli-cell tumours) [9-14] are the most common tumour types observed. Gonadoblastoma [15] and non-seminomas (yolk sac tumour [16], embryonal carcinoma [17]) have been reported as well.

References

- Loy CJ, Yong EL. Sex, infertility and the molecular biology of the androgen receptor. *Curr Opin Obstet Gynecol* 2001; 13: 315-321.
- Rutgers JL, Scully RE. The androgen insensitivity syndrome (testicular feminization): a clinicopathologic study of 43 cases. *Int J Gynecol Pathol* 1991; 10: 126-144.
- Kocak M, Yalvac S, Pata O, Turan H, Haberal A. A seminoma case which occurred in a patient with familial testicular feminization syndrome. *Acta Obstet Gynecol Scand* 2000; 79: 890-891.
- Sakai N, Yamada T, Asao T, Baba M, Yoshida M, Murayama T. Bilateral testicular tumors in androgen insensitivity syndrome. *Int J Urol* 2000; 7: 390-392.
- Chan LY, Wong SF, Yu VS. Advanced stage of dysgerminoma in testicular feminisation: is radical surgery necessary? *Aust N Z J Obstet Gynaecol* 2000; 40: 224-225.
- Collins GM, Kim DU, Logrono R, Rickert RR, Zablow A, Breen JL. Pure seminoma arising in androgen insensitivity syndrome (testicular feminization syndrome): a case report and review of the literature. *Mod Pathol* 1993; 6: 89-93.
- Hurt WG, Bodurtha JN, McCall JB, Ali MM. Seminoma in pubertal patient with androgen insensitivity syndrome. *Am J Obstet Gynecol* 1989; 161: 530-531.
- Horcher E, Grünberger W, Parschalk O. Classical seminoma in a case of testicular feminization syndrome. *Prog Pediatr Surg* 1983; 16: 139-141.
- Hawkyard S, Poon P, Morgan DR. Sertoli tumour presenting with stress incontinence in a patient with testicular feminization. *BJU Int* 1999; 84: 382-383.
- Knöke I, Jakubiczka S, Ottersen T, Goppinger A, Wieacker P. A(870)E mutation of the androgen receptor gene in a patient with complete androgen insensitivity syndrome and Sertoli cell tumor. *Cancer Genet Cytogenet* 1997; 98: 139-141.
- Fleckenstein GH, Gunawan B, Brinck U, Wuttke W, Emons G. Simultaneous sertoli cell tumor and adenocarcinoma of the tunica vaginalis testis in a patient with testicular feminization. *Gynecol Oncol* 2002; 84: 460-463.
- Wysocka B, Serkies K, Debnick J, Jassem J, Limon J. Sertoli cell tumor in androgen insensitivity syndrome – a case report. *Gynecol Oncol* 1999; 75: 480-483.
- Damjanov I, Nesbitt KA, Reardon MP, Vidone RA. Giant sertoli cell adenoma in testicular feminization syndrome. *Obstet Gynecol* 1976; 48: 624-627.
- McNeill SA, O'Donnell M, Donat R, Lessells A, Hargreave TB. Estrogen secretion from a malignant sex cord stromal tumor in a patient with complete androgen insensitivity. *Am J Obstet Gynecol* 1997; 177: 1541-1542.
- Chen CP, Chen SR, Wang TY, Wang W, Hwu YM. A frame shift mutation in the DNA-binding domain of the androgen receptor gene associated with complete androgen insensitivity, persistent mullerian structures, and germ cell tumors in dysgenetic gonads. *Fertil Steril* 1999; 72: 170-173.
- Handa N, Nagasaki A, Tsunoda M, Ohgami H, Kawanami T, Sueishi K, Nagoshi M. Yolk sac tumor in a case of testicular feminization syndrome. *J Pediatr Surg* 1995; 30: 1366-1367.
- Lecca U, Parodo G, Fiore R, Martino E. Embryonal carcinoma in two cases of androgen insensitivity syndrome: clinical, endocrinological and pathological features. *Eur J Gynaecol Oncol* 1988; 9: 489-496.

Angiolipomatosis, familial**Mode of inheritance:** AD?/AR?**OMIM number:** 206550**Tumour features:**

angiolipoma

Non-tumour features (possible):

iris, Lisch nodules

Comment

Familial clustering of multiple (non-infiltrating) angiolipomas has been reported a few times, the most extensive family being that published by Kumar et al. [1]. In that family the angiolipomas were well encapsulated and located on the upper part of the body. Hapnes et al. [2] reported on a case with angiolipomas located close to joints and extending deep between muscle, tendons and joint capsules. Abbasi et al. reported an 80-year-old man with a 50-year history of asymptomatic, subcutaneous masses on the arms, trunk, and legs. His father and maternal grandmother had a history of similar lesions [3]. The distinction from familial multiple lipomatosis is not completely certain. Familial angiolipomatosis may

sometimes be clinically confused with neurofibromatosis type 1 (NF1). Interestingly, Cina et al. [4] reported the occurrence of Lisch nodules (a typical feature of NF1) in familial angioliipomatosis.

References

1. Kumar R, Pereira BJ, Sakhuja V, Chugh KS. Autosomal dominant inheritance in familial angioliipomatosis. *Clin Genet* 1989; 35: 202-204.
2. Hapnes SA, Boman H, Skeie SO. Familial angioliipomatosis. *Clin Genet* 1980; 17: 202-208.
3. Abbasi NR, Brownell I, Fangman W. Familial multiple angioliipomatosis. *Dermatology Online J* 2007; 13: 3.
4. Cina SJ, Radentz SS, Smialek JE. A case of familial angioliipomatosis with Lisch nodules. *Arch Pathol Lab Med* 1999; 123: 946-948.

Arrhenoblastoma and thyroid adenoma, familial

Synonym: including arrhenoblastoma, familial clustering

Mode of inheritance: AD

OMIM number: 107950

Tumour features:

ovarian Sertoli-Leydig cell tumour

thyroid adenoma

Tumour features (possible):

hamartomatous polyps in small intestine

ovarian mucinous cystadenoma

Wilm's tumour

Non-tumour features:

thyroid hyperplasia/goitre

Comment

A number of families with multiple cases of ovarian Sertoli-Leydig cell tumours (arrhenoblastomas) have been reported. In some of these families (multiple) thyroid adenomas were also present in some of the relatives with ovarian tumours as well as in relatives without these tumours [1, 2]. A mucinous cystadenoma was reported twice in these families and one case of Wilms' tumour was reported [1]. In the proband published by O'Brien et al. [2], a hamartous polyp was removed from the small intestine at the age of 3 months. Could this disorder be a variant of Cowden syndrome or Peutz-Jeghers syndrome?

References

1. Jensen RD, Norris HJ, Fraumeni JF Jr. Familial arrhenoblastoma and thyroid adenoma. *Cancer* 1974; 33: 218-223.
2. O'Brien PK, Wilansky DL. Familial thyroid nodulation and arrhenoblastoma. *Am J Clin Pathol* 1981; 75: 578-581.

Ataxia pancytopenia syndrome

Synonym: myelocerebellar disorder

Mode of inheritance: AD

OMIM number: 159550

Tumour features:

lung haemangioma

Non-tumour features:

bone marrow monosomy 7 karyotype

cerebellar ataxia

nerve conduction velocity, reduced

pancytopenia

Comment

This condition is characterized by pancytopenia, progressive cerebellar ataxia, reduced nerve conduction speed and acute myelomonocytic leukaemia, which all develop in early childhood. The hypoplastic bone marrow shows cells with a monosomy 7 karyotype [1-3].

References

1. Li FP, Hecht F, Kaiser-McCaw B, Baranko PV, Potter NU. Ataxia-pancytopenia: syndrome of cerebellar ataxia, hypoplastic anemia, monosomy 7, and acute myelogenous leukemia. *Cancer Genet Cytogenet* 1981; 4: 189-196.
2. Daghistani D, Curless R, Toledano SR, Ayyar DR. Ataxia-pancytopenia and monosomy 7 syndrome. *J Pediatr* 1989; 115: 108-110.
3. González-del Angel A, Cervera M, Gómez L, Pérez-Vera P, Orozco L, Carnevale A, Del Castillo V. Ataxia-pancytopenia syndrome. *Am J Med Genet* 2000; 90: 252-254.

Ataxia telangiectasia

Synonym: AT, Louis-Bar syndrome

Mode of inheritance: AR

OMIM number: 208900

Genes:

ATM, mapped to 11q22.3

Tumour features:

astrocytoma

breast cancer

colon cancer

gastric cancer

glioma of the brain

hepatocellular cancer

histiocytosis (reticuloendotheliosis), malignant

Hodgkin's disease

laryngeal cancer

leukaemia, acute lymphoblastic (ALL)

leukaemia, chronic lymphocytic (CLL)

non-Hodgkin's lymphoma

ovarian cancer (i.e. epithelial origin)

parotid gland cancer
 skin cancer, basal cell
 skin cancer, squamous cell
 thyroid cancer

Tumour features (possible):

leiomyosarcoma of the uterus
 ovarian dysgerminoma
 ovarian fibroma
 ovarian gonadoblastoma
 seminoma
 uterine leiomyoma

Non-tumour features:

café-au-lait spots
 cerebellar ataxia
 growth deficiency
 hypogonadism
 immunodeficiency
 increased chromosomal breakage
 increased/persistent serum AFP
 ionizing radiation sensitivity, increased
 mutagen sensitivity, increased
 oculocutaneous telangiectasia
 strabismus
 thymus hypoplasia/aplasia

Comment

Progressive ataxia usually develops during infancy. Telangiectasia occurs usually first in the bulbar conjunctivae and later over the bridge of the nose, auricles and other areas. Growth deficiency commonly presents during late infancy/childhood. Mental deficiency is a feature in about half of cases [1]. Neoplasms develop in approximately 10 percent of patients, especially lymphoid tumours. Many patients do not survive to adulthood, lung infections and neurological complications being the main cause of death. Non-Hodgkin's lymphoma (mostly of the histological subtype associated with 14q translocations), acute lymphoblastic leukaemia and Hodgkin's disease (mostly of lymphocytic depletion type) are the most frequent neoplasms in AT patients [2]. Myeloid tumours are absent [3]. The increase in lymphoid malignancy is caused by both B- and T-cell tumours [3, 4]. T-cell tumours may develop at any age and may be T-ALL, T-cell lymphoma or T-cell prolymphocytic leukaemia [3]. The recognition of lymphomas may be delayed due to confusion with known infectious complications in AT [5]. A wide range of other neoplasms have been reported, including gastric cancer, colon cancer, chronic lymphoblastic leukaemia, brain tumours, craniopharyngioma, liver cancer, laryngeal cancer, leiomyoma and leiomyosarcoma of the uterus,

dysgerminoma, fibroadenoma and gonadoblastoma of the ovaries, testicular seminoma and basal cell and squamous cell skin cancer [5-13].

Inheriting one mutated copy of the AT gene (ATM) increases breast cancer risk in females, and may turn out to contribute significantly to the total breast cancer burden. However, data are inconclusive as to the magnitude of this contribution and strength of this risk factor [14-25]. Broeks et al. [26] found the relatively high percentage of 8.5% ATM mutation carriers in a group of 82 breast cancer patients selected for early onset (<45 years), long-term survival and bilaterality. Baynes et al. showed that it is unlikely that common ATM variants increase breast cancer risk [27]. Johnson et al. confirmed this and argued that it is rather a combination of variants in different genes (ATM, BRCA1, BRCA2) that confers an increased breast cancer risk [28]. However, single rare ATM alleles may still confer a substantially increased breast cancer risk [29]. Balleine et al. reported that breast cancer occurring in carriers of ATM variants is not associated with distinctive histopathological features [30].

Fibroblast cultures of AT heterozygotes show increased radiosensitivity and given the fact that breast cancer is a complication well known to occur in long-term survivors of Hodgkin's disease who received mantle-field irradiation, it has been questioned whether germline mutations in ATM contributed to this increase of breast cancer risk. Studies by Broeks et al. [31] and Nichols et al. [32] did not support a major contribution of germline ATM mutations to the breast cancer risk in these types of patients. The same was true for contralateral breast cancer risk after radiation therapy for the first breast tumour, as reported by Shafman et al. [33].

References

1. Boder E. Ataxia-telangiectasia: some historic, clinical and pathologic observations. *Birth Defects Orig Artic Ser* 1975; 11: 255-270.
2. Frizzera G, Rosai J, Dehner LP, Spector BD, Kersey JH. Lymphoreticular disorders in primary immunodeficiencies: new findings based on an up-to-date histologic classification of 35 cases. *Cancer* 1980; 46: 692-699.
3. Taylor AM, Metcalfe JA, Thick J, Mak YF. Leukemia and lymphoma in ataxia telangiectasia. *Blood* 1996; 87: 423-438.
4. Kaneko H, Inoue R, Yamada Y, Kasahara K, Takami T, Kondo N. Ataxia telangiectasia syndrome with B cell lymphoma. *Clin Genet* 1996; 49: 331-332.
5. Murphy RC, Berdon WE, Ruzal-Shapiro C, Hall EJ, Kornecki A, Daneman A, Brunelle F, Campbell JB. Malignancies in pediatric patients with ataxia telangiectasia. *Pediatr Radiol* 1999; 29: 225-230.

6. Hecht F, Hecht BK. Cancer in ataxia-telangiectasia patients: 10th anniversary article. *Cancer Genet Cytogenet* 1990; 46: 9-19.
7. Penn I. Occurrence of cancer in immune deficiencies. *Cancer* 1974; 34 Suppl: 858-866.
8. Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency diseases. A literature review. *Cancer* 1971; 28: 89-98.
9. Miyagi K, Mukawa J, Kinjo N, Horikawa K, Mekar S, Nakasone S, Koga H, Higa Y, Naito M. Astrocytoma linked to familial ataxia-telangiectasia. *Acta Neurochir (Wien)* 1995; 135: 87-92.
10. Phillips HA, Howard GC. Testicular seminoma in a patient with ataxia-telangiectasia. *Clin Oncol (R Coll Radiol)* 1999; 11: 63-64.
11. Weinstein S, Scottolini AG, Loo SY, Caldwell PC, Bhagavan NV. Ataxia telangiectasia with hepatocellular carcinoma in a 15-year-old girl and studies of her kindred. *Arch Pathol Lab Med* 1985; 109: 1000-1004.
12. Koksai Y, Caliskan U, Ucar C, Yurtcu M, Artac H, Ilerisoy-Yakut Z, Reisli I. Dysgerminoma in a child with ataxia-telangiectasia. *Pediatric Hematol Oncol* 2007; 24: 431-436.
13. Masri AT, Bakri FG, Al-Hadidy AM, Musharbash AF, Al-Hussaini M. Ataxia-telangiectasia complicated by craniopharyngioma – a new observation. *Pediatr Neurol* 2006; 35: 287-288.
14. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. *N Engl J Med* 1991; 325: 1831-1836.
15. Easton DF. Cancer risks in A-T heterozygotes. *Int J Radiat Biol* 1994; 66 (6 Suppl): S177-S182.
16. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, Ashkenazi M, Pecker I, Frydman M, Harnik R, Sankharam RP, Simmons A, Clines GA, Sartiel A, Gatti RA, Chessa L, Sanal O, Lavin MF, Jaspers NG, Taylor MA, Arlett CF, Miki T, Weissman SM, Lovett M, Collins FS, Shiloh Y. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. *Science* 1995; 268: 1749-1753.
17. Nowak R. Discovery of AT gene sparks biomedical bonanza. *Science* 1995; 268: 1700-1701.
18. Vorechovský I, Luo L, Lindblom A, Negrini M, Webster AD, Croce CM, Hammarström L. ATM mutations in cancer families. *Cancer Res* 1996; 56: 4130-4133.
19. Vorechovsky I, Rasio D, Luo LP, Monaco C, Hammarström L, Webster AD, Zaloudik J, Barbanti-Brodano G, James M, Russo G, Croce CM, Negrini M. The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutation. *Cancer Res* 1996; 56: 2726-2732.
20. Athma P, Rappaport R, Swift M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. *Cancer Genet Cytogenet* 1996; 92: 130-134.
21. FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, Finkelstein DM, Isselbacher KJ, Haber DA. Heterozygous ATM mutations do not contribute to early onset of breast cancer. *Nat Genet* 1997; 15: 307-310.
22. Bishop DT, Hopper J. AT-tributable risks? *Nat Genet* 1997; 15: 226.
23. Chen J, Birkholtz GG, Lindblom P, Rubio C, Lindblom A. The role of ataxia-telangiectasia heterozygotes in familial breast cancer. *Cancer Res* 1998; 58: 1376-1379.
24. Swift M, Chase CL, Morrell D. Cancer predisposition of ataxia-telangiectasia heterozygotes. *Cancer Genet Cytogenet* 1990; 46: 21-27.
25. Janin N, Andrieu N, Ossian K, Lauge A, Croquette MF, Griscelli C, Debre M, Bressac-de Paillerets B, Aurias A, Stoppa-Lyonnet D. Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in french AT families. *Br J Cancer* 1999; 80: 1042-1045.
26. Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, Devilee P, Russell NS, van Leeuwen FE, van't Veer LJ. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. *Am J Hum Genet* 2000; 66: 494-500.
27. Baynes C, Healey CS, Pooley KA, Scollen S, Luben RN, Thompson DJ, Pharoah PD, Easton DF, Ponder BA, Dunning AM; SEARCH breast cancer study. Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. *Breast Cancer Res* 2007; 9: R27.
28. Johnson N, Fletcher O, Palles C, Rudd M, Webb E, Sellick G, dos Santos Silva I, McCormack V, Gibson L, Fraser A, Leonard A, Gilham C, Tavtigian SV, Ashworth A, Houlston R, Peto J. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. *Hum Mol Genet* 2007; 16: 1051-1057.
29. Bernstein JL, Teraoka S, Southey MC, Jenkins MA, Andrulis IL, Knight JA, John EM, Lapinski R, Wolitzer AL, Whittemore AS, West D, Seminara D, Olson ER, Spurdle AB, Chenevix-Trench G, Giles GG, Hopper JL, Concannon P. Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. *Hum Mutat* 2006; 27: 1122-1128.
30. Balleine RL, Murali R, Bilous AM, Farshid G, Waring P, Provan P, Byth K, Thorne H, kConFab Investigators, Kirk JA. Kirk JA. Histopathological features of breast cancer in carriers of ATM gene variants. *Histopathology* 2006; 49: 523-532.
31. Broeks A, Russell NS, Floore AN, Urbanus JH, Dahler EC, van't Veer MB, Hagenbeek A, Noordijk EM, Crommelin MA, van Leeuwen FE, van't Veer LJ. Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations. *Int J Radiat Biol* 2000; 76: 693-698.
32. Nichols KE, Levitz S, Shannon KE, Wahrer DC, Bell DW, Chang G, Hegde S, Neuberg D, Shafman T, Tarbell NJ, Mauch P, Ishioka C, Haber DA, Diller L. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. *J Clin Oncol* 1999; 17: 1259.
33. Shafman TD, Levitz S, Nixon AJ, Gibans LA, Nichols KE, Bell DW, Ishioka C, Isselbacher KJ, Gelman R, Garber J, Harris JR, Haber DA. Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor. *Gene Chrom Cancer* 2000; 27: 124-129.

Autoimmune lymphoproliferative syndrome, type I

Synonym: Canale-Smith syndrome, ALPS type I (including: ALPS1A, ALPS1B), including autoimmune lymphoproliferative disease (ALD)

Mode of inheritance: AD

OMIM number: 601859, 134637

Genes:

APT1/FAS, mapped to 10q24.1

Tumour features:

Burkitt lymphoma

Hodgkin's disease

non-Hodgkin's lymphoma

Tumour features (possible):

hepatocellular cancer

Non-tumour features:

autoimmune disease

Comment

This disorder develops in early childhood because of a defective lymphocyte apoptosis. It is characterized by non-malignant lymphadenopathy, splenomegaly and autoimmune disease [1]. In the majority of patients a heterozygous mutation in APT1 has been detected. APT1 encodes the Fas protein, which is a mediator of lymphocyte apoptosis. Of 46 ALPS1 patients with APT1 mutations studied at the NIH, 6 (13%) developed a lymphoma: Hodgkin's, Burkitt's, follicular lymphoma or non-Hodgkin's lymphoma [2, 3]. A case of hepatocellular carcinoma has also been reported. In general, risk for non-Hodgkin's lymphoma and Hodgkin's disease is increased.

Ramenghi et al. [4] reported an ALPS-like disorder, which they referred to as autoimmune lymphoproliferative disease (ALD), associated with decreased Fas function in the absence of detectable Fas mutations. Hodgkin's disease was reported by them to have occurred in one of these ALD families and the frequency of cancer in general was increased in the families' maternal lines.

References

1. Straus SE, Sneller M, Lenardo MJ, Puck JM, Strober W. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. *Ann Intern Med* 1999; 130: 591-601.
2. Jackson CE, Wang J, Fischer RE, Hsu AP, Niemela J, Dale JK, Fleischer TA, Jaffe ES, Lenardo MJ, Straus SE, Puck JM. Autoimmune lymphoproliferative syndrome (ALPS): an disorder of apoptosis with predisposition to development of diverse lymphomas. *Am J Hum Genet* 1999; 65: A48.
3. Rao VK, Straus SE. Causes and consequences of the autoimmune lymphoproliferative syndrome. *Hematology* 2006; 11: 15-23.
4. Ramenghi U, Bonissoni S, Migliaretti G, DeFranco S, Bottarel F, Gambaruto C, DiFranco D, Priori R, Conti F, Dianzani I, Valesini G, Merletti F, Dianzani U. Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer. *Blood* 2000; 95: 3176-3182.

Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy

Synonym: APECED

Mode of inheritance: AR

OMIM number: 240300

Genes:

AIRE, mapped to 21q22.3

Tumour features:

oesophagus, squamous cell cancer of the intraoral squamous cell cancer

Non-tumour features:

alopecia

autoimmune disease

candidiasis

cataract

dental abnormalities

diabetes mellitus

hypogonadism

hypoparathyroidism

hypothyroidism

keratopathy

nails, dystrophic

Comment

This rare autoimmune disorder mainly affects the endocrine glands [parathyroid glands (85%), adrenal cortex (72%) and ovaries (60%)] and is associated with enamel hypoplasia (77%), nail dystrophy (52%), keratopathy (22%) and candidiasis (100%). Oral squamous cell cancer and severe autoimmune hepatitis are the most life-threatening complications [1-3]. Perheentupa reported oral or oesophageal squamous cell carcinoma in 10% of patients older than 25 years in a relatively large Finnish series [4].

References

1. Björnses P, Aaltonen J, Horelli-Kuitunen N, Yaspo ML, Peltonen L. Gene defect behind APECED: a new clue to autoimmunity. *Hum Mol Genet* 1998; 7: 1547-1553.
2. Firth NA, O'Grady JF, Reade PC. Oral squamous cell carcinoma in a young person with candidosis endocrinopathy syndrome: a case report. *Int J Oral Maxillofac Surg* 1997; 26: 42-44.
3. McGurk M, Holmes M. Chronic muco-cutaneous candidiasis and oral neoplasia. *J Laryng Otol* 1988; 102: 643-645.
4. Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. *J Clin Endocrinol Metab* 2006; 91: 2843-2850.

Bannayan-Riley-Ruvalcaba syndrome

Synonym: subset of PTEN-MATCH, including Ruvalcaba-Myhre-Smith syndrome

Mode of inheritance: AD

OMIM number: 153480

Genes:

PTEN, mapped to 10q23.3

Tumour features:

facial papules

hamartomatous polyps in colon/rectum

hamartomatous polyps in small intestine

haemangioma

lipoma

oral papules

trichilemmoma

Tumour features (possible):

breast cancer
meningioma
thyroid adenoma
thyroid cancer

Non-tumour features:

cornea, prominent nerves
deafness
gross motor delay
high birth weight
hypotonia
joint laxity
lipid storage myopathy of proximal muscles
macrocephaly
mental deficiency
pectus excavatum
pigmented macules on glans and shaft of penis
scoliosis
seizures
vulvar lentigines

Comment

Lipid storage myopathy, pigmented macules on glans and shaft of penis and vulva, intestinal hamartous (juvenile type) polyps and neurodevelopmental delay are the typical features [1-9]. A clinical overlap with Cowden disease has been noted and indeed germline mutations in the PTEN gene, involved in Cowden disease, have been detected in this disorder. It should therefore be considered as a variant of Cowden syndrome [10-15]. DiLiberti [10] has recently proposed the nomenclature PTEN-MATCHS (macrocephaly, autosomal dominant, thyroid disease, cancer, hamartomata, skin abnormalities) to cover the clinical spectrum associated with germline PTEN mutations.

References

1. Gujrati M, Thomas C, Zelby A, Jensen E, Lee JM. Bannayan-Zonana syndrome: a rare autosomal dominant syndrome with multiple lipomas and hemangiomas: a case report and review of literature. *Surg Neurol* 1998; 50: 164-168.
2. Fargnoli MC, Orlov SJ, Semel-Concepcion J, Bologna JL. Clinicopathologic findings in the Bannayan-Riley-Ruvalcaba syndrome. *Arch Dermatol* 1996; 132: 1214-1218.
3. Miles JH, Zonana J, McFarlane J, Aleck KA, Bawle E. Macrocephaly with hamartomas: Bannayan-Zonana syndrome. *Am J Med Genet* 1984; 19: 225-234.
4. Foster MA, Kilcoyne RF. Ruvalcaba-Myhre-Smith syndrome: a new consideration in the differential diagnosis of intestinal polyposis. *Gastrointest Radiol* 1986; 11: 349-350.
5. Gretzula JC, Hevia O, Schachner LS, DiLiberti JH, Ruvalcaba RH, Schimschock JR, Weleber RG, Halal F, Lipson MH, Blumberg B, et al. Ruvalcaba-Myhre-Smith syndrome. *Pediatr Dermatol* 1988; 5: 28-32.

6. Gorlin RJ, Cohen MM Jr, Condon LM, Burke BA. Bannayan-Riley-Ruvalcaba syndrome. *Am J Med Genet* 1992; 44: 307-314.
7. Hayashi Y, Ohi R, Tomita Y, Chiba T, Matsumoto Y, Chiba T. Bannayan-Zonana syndrome associated with lipomas, hemangiomas, and lymphangiomas. *J Pediatr Surg* 1992; 27: 722-723.
8. Higginbottom MC, Schultz P. The Bannayan syndrome: an autosomal dominant disorder consisting of macrocephaly, lipomas, hemangiomas, and risk for intracranial tumors. *Pediatrics* 1982; 69: 632-634.
9. Lowichik A, White FV, Timmons CF, Weinberg AG, Gunasekaran TS, Nathan K, Coffin CM. Bannayan-Riley-Ruvalcaba syndrome: spectrum of intestinal pathology including juvenile polyps. *Pediatr Dev Pathol* 2000; 3: 155-161.
10. DiLiberti JH. Inherited macrocephaly-hamartoma syndromes. *Am J Med Genet* 1998; 79: 284-290.
11. Marsh DJ, Dahia PL, Zheng ZM, Liaw D, Parsons R, Gorlin RJ, Eng C. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. *Nat Genet* 1997; 16: 333-334.
12. Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z, Liaw D, Caron S, Duboué B, Lin AY, Richardson AL, Bonnetblanc JM, Bressieux JM, Cabarrot-Moreau A, Chompret A, Demange L, Eeles RA, Yahanda AM, Fearon ER, Fricker JP, Gorlin RJ, Hodgson SV, Huson S, Lacombe D, Eng C, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. *Hum Mol Genet* 1998; 7: 507-515.
13. Longy M, Coulon V, Duboué B, David A, Larrègue M, Eng C, Amati P, Kraimps JL, Bottani A, Lacombe D, Bonneau D. Mutations of PTEN in patients with Bannayan-Riley-Ruvalcaba phenotype. *J Med Genet* 1998; 35: 886-889.
14. Lachlan KL, Lucassen AM, Bunyan D, Temple IK. Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers. *J Med Genet* 2007; 44: 579-585.
15. Hendriks YM, Verhallen JT, van der Smagt JJ, Kant SG, Hilhorst Y, Hoefsloot L, Hansson KB, van der Straaten PJ, Boutkan H, Breuning MH, Vasen HF, Bröcker-Vriends AH. Bannayan-Riley-Ruvalcaba syndrome: further delineation of the phenotype and management of PTEN mutation-positive cases. *Fam Cancer* 2003; 2: 79-85.

Bardet-Biedl syndrome

Synonym: BBS, Bardet-Biedl syndrome, type 1-12: BBS1-12

Mode of inheritance: AR

OMIM number: 209901, 209900, 600151, 600374, 603650, 605231

Genes:

BBS1, mapped to 11q13
BBS10, mapped to 12q
BBS11, mapped to 9q33.1
BBS12, mapped to 4q27
BBS2, mapped to 16q21
BBS3, mapped to 3p12-q13
BBS4, mapped to 15q22.3
BBS5, mapped to 2q31

BBS6/MKKS, mapped to 20p12

BBS7, mapped to 4q27

BBS8, mapped to 14q32.11

BBS9, mapped to 7p14

Tumour features (possible):

renal cell cancer, clear-cell

Non-tumour features:

brachydactyly, of feet

brachydactyly, of hands

deafness, conductive

dental abnormalities

hypogonadism

mental deficiency

obesity

polydactyly, postaxial

renal anomalies

renal dysplasia

rod-cone dystrophy

Comment

This disorder (BBS) is characterized by postaxial polydactyly, central obesity, rod-cone dystrophy, mental retardation and renal dysfunction. Beales et al. [1] observed 3 cases of clear cell renal cell carcinoma (diagnosed at age 37, 40 and 52, respectively) among 180 parents of BBS patients. This is more than expected in the normal population ($p=0.0007$). The authors calculated that parents of BBS children have a relative risk of 17 (95% CI=3.6-49.9) of developing clear cell renal cell cancer before the age of 55 years. One of the tumours showed loss of heterozygosity at the BBS1 locus. The authors suggest that the BBS genes may be implicated in the development of renal cancer (and renal malformation). In contrast, Hjortshøj et al. found no evidence for an increased cancer risk in BBS patients and their relatives [2].

References

1. Beales PL, Reid HA, Griffiths MH, Maher ER, Flinter FA, Woolf AS. Renal cancer and malformations in relatives of patients with Bardet-Biedl syndrome. *Nephrol Dial Transplant* 2000; 15: 1977-1985.
2. Hjortshøj TD, Grønskov K, Rosenberg T, Brøndum-Nielsen K, Olsen JH. Risk for cancer in patients with Bardet-Biedl syndrome and their relatives. *Am J Med Genet A* 2007; 143: 1699-1702.

Barrett's oesophagus, familial

Mode of inheritance: AD?/multifactorial

OMIM number: 109350

Tumour features:

oesophagus, adenocarcinoma of the

Tumour features (possible):

colorectal cancer

colorectal polyps

gastric cancer

tongue cancer

Non-tumour features:

oesophagus, Barrett's

Comment

Barrett's oesophagus and oesophageal adenocarcinoma are complications of gastroesophageal reflux [1], which may show familial clustering, as has been demonstrated by Romero et al. [2]. These authors reported that reflux symptoms were significantly more prevalent among parents and siblings of patients with oesophageal adenocarcinoma and/or Barrett's oesophagus than among controls. Other authors have reported familial cases as well. Hampel et al. [3] reported on 3 families and suggested that Barrett's oesophagus families possibly are at an increased risk of developing extra-oesophageal cancer (notably of the digestive tract) as well. More recently more familial clusters have been reported [4-8] and family history is an acknowledged risk factor. Chak et al. showed that a family history of Barrett's oesophagus can be confirmed in 7.3% of persons presenting with Barrett's oesophagus, adenocarcinoma of the oesophagus, or adenocarcinoma of the gastroesophageal junction [5]. Linkage analyses are underway [9].

References

1. Van den Boogert J, van Hillegersberg R, de Bruin RW, Tilanus HW, Siersema PD. Barrett's oesophagus: pathophysiology, diagnosis, and management. *Scand J Gastroenterol* 1998; 33: 449-453.
2. Romero Y, Cameron AJ, Locke GR 3rd, Schaid DJ, Slezak JM, Branch CD, Melton LJ. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. *Gastroenterology* 1997; 113: 1449-1456.
3. Hampel H, Poling BA, Curtis M, Mascari M, Fromkes JJ, Eng C. Familial Barrett esophagus: a true hereditary cancer syndrome. *Am J Hum Genet* 1999; 65: A40.
4. Chak A, Lee T, Kinnard MF, Brock W, Faulx A, Willis J, Cooper GS, Sivak MV, Goddard KA. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. *Gut* 2002; 51: 323-328.
5. Chak A, Ochs-Balcom H, Falk G, Grady WM, Kinnard M, Willis JE, Elston R, Eng C. Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. *Cancer Epidemiol Biomarkers Prev* 2006; 15: 1668-1673.
6. Groves C, Jankowski J, Barker F, Holdstock G. A family history of Barrett's oesophagus: another risk factor? *Scand J Gastroenterol* 2005; 40: 1127-1128.

7. Melzer E, Shtoyerman R, Appelman Z, Kashtan H. Familial Barrett's adenocarcinoma. *Am J Gastroenterol* 2006; 101: 677.
8. Sappati Biyyani RS, Chessler L, McCain E, Nelson K, Fahmy N, King J. Familial trends of inheritance in gastro esophageal reflux disease, Barrett's esophagus and Barrett's adenocarcinoma: 20 families. *Diseases of the Esophagus* 2007; 20: 53-57.
9. Ochs-Balcom HM, Falk G, Grady WM, Kinnard M, Willis J, Elston R, Eng C, Chak A. Consortium approach to identifying genes for Barrett's esophagus and esophageal adenocarcinoma. *Transl Res* 2007; 150: 3-17.

Basal cell nevus syndrome

Synonym: Gorlin syndrome, Gorlin-Golz syndrome, naevoid basal cell carcinoma syndrome

Mode of inheritance: AD

OMIM number: 109400

Genes:

PTCH, mapped to 9q22.3

Tumour features:

cardiac fibroma
infundibulocystic basal cell cancer
medulloblastoma
ovarian fibroma
skin cancer, basal cell

Tumour features (possible):

astrocytoma
breast cancer
dermoid cyst, nasal
ependymoma
Hodgkin's disease
leiomyoma
leiomyosarcoma
leukaemia, acute lymphoblastic (ALL)
leukaemia, chronic lymphocytic (CLL)
lung/bronchial cancer
malignant melanoma, cutaneous
meningioma
multiple myeloma
nasopharyngeal rhabdomyosarcoma
non-Hodgkin's lymphoma
ovarian fibrosarcoma
ovarian sarcoma (including pPNET of ovary)
renal cell cancer
renal fibroma
rhabdomyoma, fetal
rhabdomyosarcoma
salivary gland tumour
salivary gland, adenoid cystic carcinoma
seminoma
teratoma, benign cystic (dermoid cyst) of the ovary
thyroid adenoma
urinary bladder cancer
Wilms' tumour (nephroblastoma)

Non-tumour features:

café-au-lait spots
epidermoid cysts
falx cerebri, calcification of
frontoparietal bossing
hypertelorism
ionizing radiation sensitivity, increased
jaw, odontogenic keratocysts of the
nasal bridge, broad
palate, high arched
palmar pits
pectus excavatum/carinatum
plantar pits
prognathism
rib anomalies
sloping shoulders
strabismus
vertebral anomalies

Comment

In this disorder, multiple nevoid basal cell cancers (NBCC) typically start to appear at the age of puberty, although they have been reported to occur as early as 3 years of age. The NBCCs may manifest anywhere on the skin, but mainly on the face, neck and upper trunk. A typical facies is often present (70%), featuring frontoparietal bossing, broad nasal bridge and prognathism. Skeletal anomalies are often detected (e.g. 80% of patients are diagnosed with keratocysts of the jaw before the age of 30), as well as palmoplantar skin pits (87% of patients [1]). Mental deficiency occurs in a few cases [1-4].

A wide range of tumours has been reported in basal cell nevus syndrome in addition to basal cell carcinomas: ovarian fibromas occur in frequencies ranging from 14 to over 50%. Medulloblastoma, ages at diagnosis ranging from 2 months to 7 years and of the desmoplastic subtype [5], is considered to be part of the tumour spectrum [6] and has been included as a minor criterion for the disorder (see below). However, it is still relatively rare: 4 out of 105 patients studied by Kimonis et al. [1]. Cardiac fibromas [7, 8] have been included as a minor criterion as well. Other reported tumours include: rhabdomyosarcoma [9, 10], (malignant) meningioma [1, 11], astrocytoma [4, 12, 13], cerebellar ependymoma [1], hamartous polyps of the stomach [14], fetal rhabdomyoma [15], nasal dermoid cyst [16], NHL [4], ovarian dermoid cyst [4], CLL [4], ALL [13], breast cancer [4], lung cancer [4], ovarian fibrosarcoma [2] and ovarian leiomyosarcoma [17], leiomyosarcoma of the extremities [18], seminoma [19], carcinoma of the vulva

[20], adenoid cystic carcinoma of the salivary glands [21] and others [2]. Rhabdomyosarcoma and Wilms' tumour were diagnosed in a girl with a deletion of 9q22-q32 which included the PTCH gene [22].

Patients with the syndrome have an increased risk of developing secondary tumours in the field of radiation treatment. A conservative estimate of the new mutation rate in basal cell nevus syndrome is 14% [4]. Fukushima et al. [23] reported the occurrence of a meningioma after radiation treatment for a medulloblastoma.

The gene for basal cell nevus syndrome has been identified as the human homologue of the *Drosophila* patched gene [24, 25].

Diagnostic criteria:

two major criteria or one major + two minor criteria should be present.

Major:

- multiple basal cell carcinomas, or one under the age of 30 years, or >10 basal cell nevi; in a sunny climate these numbers should be higher (not further specified),
- histologically proven odontogenic keratocyst, or polyostotic bone cyst,
- >3 palmar and/or plantar pits,
- calcification of the falx cerebri: lamellar or early (<20 years),
- first-degree relative with nevoid basal cell carcinomas.

Minor:

- congenital skeletal anomaly: bifid, fused, splayed or missing rib or fused vertebrae,
- macrocephaly (occipitofrontal circumference > 97th centile) with bossing,
- cardiac or ovarian fibroma,
- medulloblastoma,
- lymphomesenteric cysts,
- congenital malformation: cleft lip and/or palate, polydactyly, eye anomaly (cataract, coloboma, microphthalmia).

References

1. Kimonis VE, Goldstein AM, Pastakia B, Yang ML, Kase R, DiGiovanna JJ, Bale AE, Bale SJ. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. *Am J Med Genet* 1997; 69: 299-308.
2. Gorlin RJ. Nevoid basal-cell carcinoma syndrome. *Medicine* 1987; 66: 98-113.
3. Woolgar JA, Rippin JW, Taylor M, Browne RM. The basal cell naevus syndrome. *Br J Hosp Med* 1987; 38: 344-350.
4. Shanley S, Ratcliffe J, Hockey A, Haan E, Oley C, Ravine D, Martin N, Wicking C, Chenevix-Trench G. Nevoid basal cell carcinoma syndrome: review of 118 affected individuals. *Am J Med Genet* 1994; 50: 282-290.
5. Amlashi SF, Riffaud L, Brassier G, Morandi X. Nevoid basal cell carcinoma syndrome: relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature. *Cancer* 2003; 98: 618-624.
6. Evans DG, Farndon PA, Burnell LD, Gattamaneni HR, Birch JM. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. *Br J Cancer* 1991; 64: 959-961.
7. Evans DG, Ladusans EJ, Rimmer S, Burnell LD, Thakker N, Farndon PA. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. *J Med Genet* 1993; 30: 460-464.
8. Cotton JL, Kavey RE, Palmier CE, Tunnessen WW Jr. Cardiac tumors and the nevoid basal cell carcinoma syndrome. *Pediatrics* 1991; 87: 725-728.
9. Bddis IR, Mott MG, Bullimore J. Case report: nasopharyngeal rhabdomyosarcoma and Gorlin's naevoid basal cell carcinoma syndrome. *Med Pediatr Oncol* 1983; 11: 178-179.
10. Schweisguth O, Gerard-Marchant R, Lemerle J. Naevomatose baso-cellulaire association a un rhabdomyosarcome congenital. *Arch Fr Ped* 1968; 25: 1083-1093.
11. Albrecht S, Goodman JC, Rajagopalan S, Levy M, Cech DA, Cooley LD. Malignant meningioma in Gorlin's syndrome: Cytogenetic and p53 gene analysis. Case report. *J Neurosurg* 1994; 81: 466-471.
12. Evans DG, Birch JM, Orton CI. Brain tumours and the occurrence of severe invasive basal cell carcinoma in first degree relatives with Gorlin syndrome. *Br J Neurosurg* 1991; 5: 643-646.
13. Dinehart SM, Anthony JL, Pollack SV. Basal cell carcinoma in young patients after irradiation for childhood malignancy. *Med Pediatr Oncol* 1991; 19: 508-510.
14. Schwartz RA. Basal-cell-nevus syndrome and gastrointestinal polyposis. *N Engl J Med* 1978; 299: 49.
15. Hardisson D, Jimenez-Heffernan JA, Nistal M, Picazo ML, Tovar JA, Contreras F. Neural variant of fetal rhabdomyoma and naevoid basal cell carcinoma syndrome. *Histopathology* 1996; 29: 247-252.
16. Pivnick EK, Walter AW, Lawrence MD, Smith ME. Gorlin syndrome associated with midline nasal dermoid cyst. *J Med Genet* 1996; 33: 704-706.
17. Seracchioli R, Colombo FM, Bagnoli A, Trengia V, Venturoli S. Primary ovarian leiomyosarcoma as a new component in the nevoid basal cell carcinoma syndrome: a case report. *Am J Obst Gynecol* 2003; 188: 1093-1095.
18. Garcia-Prats MD, Lopez-Carreira M, Mayordomo JI, Ballestin C, Rivera F, Diaz-Puente MT, Muñoz M, Cortes-Funes H, Martinez-Tello F. Leiomyosarcoma of the soft tissues in a patient with nevoid basal-cell carcinoma syndrome. *Tumori* 1994; 80: 401-404.
19. Zaun H. Basalzellnavussyndrom mit ungewöhnlicher begleitsymptomatik. *Hautarzt* 1981; 32: 455-458.
20. Giuliani M, Di Stefano L, Zoccali G, Angelone E, Leocata P, Mascaretti G. Gorlin syndrome associated with basal cell carcinoma of the vulva: a case report. *Eur J Gynaecol Oncol* 2006; 27: 519-522.
21. Yilmaz B, Goldberg LH, Schechter NR, Kemp BL, Ruiz H. Basal cell nevus syndrome concurrent with adenoid cystic carcinoma of salivary gland. *J Am Acad Dermatol* 2003; 48 (5 Suppl): S64-S66.
22. Cajaiba MM, Bale AE, Alvarez-Franco M, McNamara J, Reyes-Múgica M. Rhabdomyosarcoma, Wilms tumor, and deletion of the patched gene in Gorlin syndrome. *Nat Clin Pract Oncol* 2006; 3: 575-580.
23. Fukushima Y, Oka H, Utsuki S, Iwamoto K, Fujii K. Nevoid basal cell carcinoma syndrome with medulloblastoma and

meningioma – case report. *Neurol Med Chir (Tokyo)* 2004; 44: 665-668.

24. Johnson RL, Rothman AL, Xie JW, Goodrich LV, Bare JW, Bonifas JM, Quinn AG, Myers RM, Cox DR, Epstein EH Jr, Scott MP. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. *Science* 1996; 272: 1668-1671.
25. Hahn H, Wicking C, Zaphiropoulos PG, Gailani MR, Shanley S, Chidambaram A, Vorechovsky I, Holmberg E, Unden AB, Gillies S, Negus K, Smyth I, Pressman C, Leffell DJ, Gerrard B, Goldstein AM, Dean M, Tottgard R, Chenevixtrench G, Wainwright B, Bale AE. Mutations of the human homolog of *Drosophila* patched in the nevoid basal cell carcinoma syndrome. *Cell* 1996; 85: 841-851.

Basal or squamous cell skin cancer, familial clustering of

Synonym: familial non-melanoma skin cancer

Mode of inheritance: multifactorial

Genes: many low penetrant gene mutations have been reported, we do not list them separately here

Tumour features:

skin cancer, basal cell

skin cancer, squamous cell

Tumour features (possible):

malignant melanoma, cutaneous

melanoma, uveal (choroidal, ciliary body, iris)/ocular

Comment

The influence of a family history of skin cancer on basal cell skin cancer (BCC) risk is controversial. Two studies could not demonstrate a familial risk factor [1, 2]. However, Wallberg et al. [3] found a family history of skin cancer (not further specified) among siblings and/or parents to be the strongest risk factor (RR 10.9) of 12 factors tested. The authors could not explain this risk by correcting for hereditary pigmentary characteristics, such as skin type, eye and hair colour, which are known to be associated with melanoma as well as non-melanoma skin cancer risk [4]. Hogan et al. [5] also found that a family history of skin cancer was associated with an increased risk of developing BCC (RR 1.22). In their series of 538 BCC patients and matched controls, they also observed a significantly lower age at diagnosis in those BCC patients with a family history of skin cancer compared with those who did not. In a case-control study of similar size, Naldi et al. [6] confirmed the significant association of BCC and a family history of skin cancer (odds ratio 6.7). In a population-based cohort study of twins, the co-twin of a twin affected with BCC cancer was shown to have an increased BCC risk (RR 7-8); however, zygosity did not influence this risk [7, 8]. In general, BCC in children in the absence of known

genetic conditions is rare, but has been diagnosed at the age of 4 years and older [9].

Polymorphisms of members of the glutathione-S-transferase and cytochrome P450 enzyme families have been associated with an increased risk of developing (multiple) BCC [10-12].

For squamous cell skin cancer (SCC), a positive family history of skin cancer in general also increases SCC risk, as has been calculated by Hogan et al. [13], Gamble et al. [14] and Hemminki and Dong [15]. The latter study from the Swedish Family-Cancer Database reported SIRs of 2.4 for invasive SCC and 2.8 for invasive SCC in the offspring of parents with SCC. SIR for SCC in offspring of parents with multiple SCC was 70% higher than in offspring of parents with single SCC. The authors also reported a familial association between SCC and skin and ocular melanoma.

References

1. Maia M, Proenca NG, de Moraes JC. Risk factors for basal cell carcinoma: a case-control study. *Rev Saude Publica* 1995; 29: 27-37.
2. Gellin GA, Kopf AW, Garfinkel L. Basal cell epithelioma: a controlled study of associated factors. *Arch Dermatol* 1965; 91: 38-45.
3. Wallberg P, Kaaman T, Lindberg M. Multiple basal cell carcinoma: a clinical evaluation of risk factors. *Acta Derm Venereol* 1998; 78: 127-129.
4. Armstrong BK, Kricke A. Epidemiology of sun exposure and skin cancer. *Cancer Surv* 1996; 26: 133-153.
5. Hogan DJ, To T, Gran L, Wong D, Lane PR. Risk factors for basal cell carcinoma. *Int J Dermatol* 1989; 28: 591-594.
6. Naldi L, DiLandro A, D'Avanzo B, Parazzini F. Host-related and environmental risk factors for cutaneous basal cell carcinoma: evidence from an Italian case-control study. *J Am Acad Dermatol* 2000; 42: 446-452.
7. Milan T, Kaprio J, Verkasalo PK, Jansen CT, Teppo L, Koskenvuo M. Hereditary factors in basal cell carcinoma of the skin: a population-based cohort study in twins. *Br J Cancer* 1998; 78: 1516-1520.
8. Bataille V, Snieder H, MacGregor A, Spector T. Hereditary factors in basal cell carcinoma of the skin: a population-based cohort study in twins. *Br J Cancer* 2000; 82: 247-249.
9. LeSueur BW, Silvis NG, Hansen RC. Basal cell carcinoma in children: report of 3 cases. *Arch Dermatol* 2000; 136: 370-372.
10. Lear J, Heagerty A, Smith A, Bowers B, Jones P, Gilford J, Aldersea J, Fryer A, Strange R. Polymorphism in detoxifying enzymes and susceptibility to skin cancer. *Photochem Photobiol* 1996; 63: 424-428.
11. Lear JT, Heagerty AH, Smith A, Bowers B, Payne CR, Smith CA, Jones PW, Gilford J, Yengi L, Aldersea J, Fryer AA, Strange RC. Multiple cutaneous basal cell carcinomas: Glutathione S-transferase (GSTM1, GSTT1) and cytochrome P450 (CYP2D6, CYP1A1) polymorphisms influence tumour numbers and accrual. *Carcinogenesis* 1996; 17: 1891-1896.
12. Heagerty A, Smith A, English J, Lear J, Perkins W, Bowers B, Jones P, Gilford J, Aldersea J, Fryer A, Strange RC. Susceptibility to multiple cutaneous basal cell carcinomas: significant interactions between glutathione S-transferase GSTM1

- genotypes, skin type and male gender. *Br J Cancer* 1996; 73: 44-48.
13. Hogan DJ, Lane PR, Gran L, Wong D. Risk factors for squamous cell carcinoma of the skin in Saskatchewan, Canada. *J Dermatol Sci* 1990; 1: 97-101.
 14. Gamble JF, Lerman SE, Holder WR, Nicolich MJ, Yarborough CM. Physician-based case-control study of non-melanoma skin cancer in Baytown, Texas. *Occup Med (Lond)* 1996; 46: 186-196.
 15. Hemminki K, Dong C. Familial relationships in squamous cell carcinoma of the skin. *Epidemiology* 2000; 11: 309-314.

Bazex syndrome

Synonym: Bazex-Dupré-Christol syndrome

Mode of inheritance: XL

OMIM number: 301845

Genes:

BZX, mapped to Xq24-q27

Tumour features:

skin cancer, basal cell

Non-tumour features:

atrophoderma, follicular (ice pick marks)

facial hyperpigmentation

hair shaft dystrophy

hypotrichosis

milia

Comment

This syndrome is characterized by multiple basal cell cancers developing mainly on the face, from the second decade. The skin shows follicular atrophoderma (resembling ice pick marks), especially on the face, hands, elbows and feet. Sweating is decreased and hypotrichosis is another characteristic. The term follicular atrophoderma appears inappropriate because the skin histology does not show atrophy [1-7]. The disorder has been mapped to Xq [8].

Confusingly, the name Bazex syndrome is also used for the sporadic disorder acrokeratosis paraneoplastica, which mainly occurs in males and is characterized by psoriasiform skin lesions of predominantly ears, fingers, nose and toes, associated with squamous cell cancer of the upper aerodigestive tract [9].

References

1. Kidd A, Carson L, Gregory DW, De Silva D, Holmes J, Dean JC, Haites N. A Scottish family with Bazex-Dupre-Christol syndrome: follicular atrophoderma, congenital hypotrichosis, and basal cell carcinoma. *J Med Genet* 1996; 33: 493-497.
2. Bazex A, Dupre A, Christol B. Atrophodermic folliculaire, proliferations baso-cellulaires et hypotrichose. *Ann Dermatol Syphiligr* 1966; 93: 241-254.
3. Goeteyn M, Geerts ML, Kint A, De Weert J. The Bazex-Dupré-Christol syndrome. *Arch Dermatol* 1994; 130: 337-342.

4. Herges A, Stieler W, Stadler R. Bazex-Dupré-Christol syndrome. Follicular atrophoderma, multiple basal cell carcinomas and hypotrichosis. *Hautarzt* 1993; 44: 385-391.
5. Moreau-Cabarrot A, Bonafé JL, Hachich N, Jalby BC, Aubert G, Rolland M, Bazex J. Follicular atrophoderma, basal cell proliferation and hypotrichosis (Bazex-Dupre-Christol syndrome). A study in 2 families. *Ann Dermatol Venereol* 1994; 121: 297-301.
6. Colomb D, Ducros B, Boussuge N. Bazex, Dupré and Christol syndrome. Apropos of a case with prolymphocytic leukemia. *Ann Dermatol Venereol* 1989; 116: 381-387.
7. Mehta VR, Potdar R. Bazex syndrome. Follicular atrophoderma and basal cell epitheliomas. *Int J Dermatol* 1985; 24: 444-446.
8. Vabres P, Lacombe D, Rabinowitz LG, Aubert G, Anderson CE, Taieb A, Bonafé JL, Hors-Cayla MC. The gene for Bazex-Dupré-Christol syndrome maps to chromosome Xq. *J Invest Dermatol* 1995; 105: 87-91.
9. Bologna JL, Brewer YP, Cooper DL. Bazex syndrome (acrokeratosis paraneoplastica). An analytic review. *Medicine (Baltimore)* 1991; 70: 269-280.

Beckwith-Wiedemann syndrome

Synonym: BWS, exomphalos-macroglossia-gigantism (EMG) syndrome, Wiedemann-Beckwith syndrome, WBS

Mode of inheritance: AD/spor/impr (UPDpat11)

OMIM number: 130650

Genes:

H19, mapped to 11p15.5

LIT1/KCNQ1OT1, mapped to 11p15.5

NSD1, mapped to 5q35

p57/kip2/CDKN1C, mapped to 11p15.5

Tumour features:

adrenal adenoma

adrenocortical cancer

hepatoblastoma

pancreatoblastoma

Wilms' tumour (nephroblastoma)

Tumour features (possible):

carcinoid of the small intestine

cardiac tumour

ganglioneuroma (tosis)

gastric teratoma

glioblastoma (multiforme)

leukaemia, acute lymphoblastic (ALL)

leukaemia, acute myeloid (AML, including ANLL)

lipoma

lymphoma, malignant (Non-Hodgkin and/or Hodgkin)

mesenchymal hamartoma of the liver

neuroblastoma, extra-adrenal

ovarian gonadoblastoma

perineurioma

pheochromocytoma

rhabdomyosarcoma

testicular gonadoblastoma

umbilical myxoma

Non-tumour features:

ear-lobe grooves
 flame nevus
 gigantism/overgrowth
 heart, congenital defect
 helix, indentations on posterior rim
 hemihypertrophy
 omphalocele
 seizures
 skeletal anomalies
 tongue, macroglossia
 transitory hypoglycaemia

Comment

Gigantism, macroglossia, omphalocele and ear creases are the typical features of the syndrome [1-4]. Pancreatic hyperplasia often occurs and leads to neonatal hypoglycaemia in 30-50% of cases. Approximately 5% of children with this disorder develop tumours before the age of 8 years, mainly Wilms' tumour (60%), hepatoblastoma and neuroblastoma, but a range of other tumours have been reported [2, 5-19]. Limb asymmetry/hemihypertrophy is associated with an increased risk of tumours [10, 11] and nephromegaly appears to be a predictor of Wilms' tumour, particularly in these patients [12].

The genetics of BWS are relatively complex. Cooper et al. analysed genotype-cancer phenotype associations and concluded that the risk of neoplasia was significantly higher in UPD and IC1 defect cases than in IC2 defect and CDKN1C mutation cases. Cancer risk for all patients was estimated at 9% at age 5 years, and 24% in the UPD subgroup. UPD including WT1 was associated with renal neoplasia. In contrast, Wilms' tumour risk in the IC2 defect subgroup appears to be small [20]. Rump et al. concluded that increased tumour risk in BWS is typically associated with loss of imprinting of H19 [21].

References

1. Cohen PR, Kurzrock R. Miscellaneous genodermatoses: Beckwith-Wiedemann syndrome, Birt-Hogg-Dube syndrome, familial atypical multiple mole melanoma syndrome, hereditary tylosis, incontinentia pigmenti, and supernumerary nipples. *Dermatol Clin* 1995; 13: 211-229.
2. Beckwith JB. Vignettes from the history of overgrowth and related syndromes. *Am J Med Genet* 1998; 79: 238-248.
3. Kosseff AL, Herrmann J, Gilbert EF, Viseskul C, Lubinsky M, Opitz JM. Studies of malformation syndromes of man XXIX: the Wiedemann-Beckwith syndrome. Clinical, genetic and pathogenetic studies of 12 cases. *Eur J Pediatr* 1976; 123: 139-166.
4. Pettenati MJ, Haines JL, Higgins RR, Wappner RS, Palmer CG, Weaver DD. Wiedemann-Beckwith syndrome: presentation of

- clinical and cytogenetic data on 22 new cases and review of the literature. *Hum Genet* 1986; 74: 143-154.
5. Bex G, Becker KF, Höfler H, Van Roy F. Mutations of the human E-cadherin (CDH1) gene. *Hum Mutat* 1998; 12: 226-237.
 6. Falik-Borenstein TC, Korenberg JR, Davos I, Platt LD, Gans S, Goodman B, Schreck R, Graham JM Jr. Congenital gastric teratoma in Wiedemann-Beckwith syndrome. *Am J Med Genet* 1991; 38: 52-57.
 7. Emery LG, Shields M, Shah NR, Garbes A. Neuroblastoma associated with Beckwith-Wiedemann syndrome. *Cancer* 1983; 52: 176-179.
 8. Drut R, Jones MC. Congenital pancreatoblastoma in Beckwith-Wiedemann syndrome: an emerging association. *Pediatr Pathol* 1988; 8: 331-339.
 9. Sotelo-Avila C, Gooch 3rd WM. Neoplasms associated with the Beckwith-Wiedemann Syndrome. In: *Perspectives in Pediatric Pathology*. Rosenberg HS (ed.) Year Book Med Publ, Chicago 1973; 255-272.
 10. Wiedemann HR. Tumours and hemihypertrophy associated with Wiedemann-Beckwith syndrome. *Eur J Pediatr* 1983; 141: 129.
 11. DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. *J Pediatr* 1998; 132: 398-400.
 12. Debaun MR, Siegel MJ, Choyke PL. Nephromegaly in infancy and early childhood: a risk factor for Wilms tumor in Beckwith-Wiedemann syndrome. *J Pediatr* 1998; 132: 401-404.
 13. Muguera R, Rodriguez A, Formigo E, Montero M, Vázquez JL, Páramo C, Campos C. Pancreatoblastoma associated with incomplete Beckwith-Wiedemann syndrome: case report and review of the literature. *J Pediatr Surg* 2005; 40: 1341-1344.
 14. Cajaiba MM, Sarita-Reyes C, Zambrano E, Reyes-Múgica M. Mesenchymal hamartoma of the liver associated with features of Beckwith-Wiedemann syndrome and high serum alpha-fetoprotein levels. *Pediatr Dev Pathol* 2007; 10: 233-238.
 15. Chen L, Li Y, Lin JH. Intraneural perineurioma in a child with Beckwith-Wiedemann syndrome. *J Pediatr Surg* 2005; 40: E12-E14.
 16. Baldisserotto M, Peletti AB, Angelo de Araújo M, Pertence AP, Dora MD, Maciel EO, Gaiger AM. Beckwith-Wiedemann syndrome and bilateral adrenal pheochromocytoma: sonography and MRI findings. *Pediatr Radiol* 2005; 35: 1132-1134.
 17. Khatib Z, Levi A, Pefkarou A, Escalon E. Acute lymphocytic leukemia in a child with Beckwith-Wiedemann syndrome. *J Pediatr Hematol Oncol* 2004; 26: 45-47.
 18. Satgé D, Vidalo E, Desfarges F, de Geeter B. A third case of cardiac neoplasm in a fetus with Beckwith-Wiedemann syndrome: epicardial angiofibroma. *Fetal Diagn Therapy* 2005; 20: 44-47.
 19. Houtenbos I, Ossenkoppele GJ. Acute myeloid leukemia in a 23-year-old patient with Beckwith-Wiedemann syndrome. *Cancer Genet Cytogenet* 2002; 136: 90-91.
 20. Cooper WN, Luharia A, Evans GA, Raza H, Haire AC, Grundy R, Bowdin SC, Riccio A, Sebastio G, Blik J, Schofield PN, Reik W, Macdonald F, Maher ER. Molecular subtypes and phenotypic expression of Beckwith-Wiedemann syndrome. *Eur J Hum Genet* 2005; 13: 1025-1032.
 21. Rump P, Zeegers MP, van Essen AJ. Tumor risk in Beckwith-Wiedemann syndrome: a review and meta-analysis. *Am J Med Genet A* 2005; 136: 95-104.

Biallelic mismatch repair gene mutations associated early onset cancer

Synonym: childhood cancer syndrome

Mode of inheritance: AR

Genes:

MLH1, mapped to 3p21.3

MSH2, mapped to 2p21-p22

MSH6, mapped to 2p16

PMS2, mapped to 7p22

Tumour features:

astrocytoma

colorectal cancer

endometrial cancer

glioblastoma (multiforme)

leukaemia, acute

leukaemia, acute lymphoblastic (ALL)

leukaemia, acute myeloid (AML, including ANLL)

leukaemia, chronic myeloid (CML)

medulloblastoma

non-Hodgkin's lymphoma

oligodendroglioma

Tumour features (possible):

ovarian sarcoma (including pNET of ovary)

Wilms' tumour (nephroblastoma)

Non-tumour features:

axillary freckling

café-au-lait spots

Non-tumour features (possible):

immunodeficiency

Comment

Multiple café-au-lait spots, axillary freckling and early onset colorectal cancer, oligopolyposis, leukaemia (ALL, AML, AL-not specified, CML), non-Hodgkin's lymphoma, brain tumours (glioblastoma, astrocytoma, oligodendroglioma medulloblastoma), Wilms' tumour, ovarian neuroectodermal tumour, endometrial cancer and sometimes IgA-deficiency have been observed in patients with biallelic mutations of the mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2 [1-11].

There is overlap with HNPCC (associated with single inherited MMR mutations) and Turcot syndrome (brain tumours and colorectal polyps).

References

1. Ricciardone MD, Ozgelik T, Cevher B, Ozdag H, Tuncer M, Gürgey A, Uzunalimoglu O, Cetinkaya H, Tanyeli A, Erken E, Oztürk M. Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. *Cancer Res* 1999; 59: 290-293.
2. Wang Q, Lasset C, Desseigne F, Frappaz D, Bergeron C, Navarro C, Ruano E, Puisieux A. Neurofibromatosis and early onset of cancers in hMLH1-deficient children. *Cancer Res* 1999; 59: 294-297.
3. De Rosa M, Fasano C, Panariello L, Scarano MI, Belli G, Iannelli A, Ciciliano F, Izzo P. Evidence for a recessive inheritance

of Turcot's syndrome caused by compound heterozygous mutations within the PMS2 gene. *Oncogene* 2000; 19: 1719-1723.

4. Whiteside D, McLeod R, Graham G, Steckley JL, Booth K, Somerville MJ, Andrew SE. A homozygous germ-line mutation in the human MSH2 gene predisposes to hematological malignancy and multiple café-au-lait spots. *Cancer Res* 2002; 62: 359-362.
5. Bougeard G, Charbonnier F, Moerman A, Martin C, Ruchoux MM, Drouot N, Frébourg T. Early onset brain tumor and lymphoma in MSH2-deficient children. *Am J Hum Genet* 2003; 72: 213-216.
6. Trimbath JD, Petersen GM, Erdman SH, Ferre M, Luce MC, Giardiello FM. Café-au-lait spots and early onset colorectal neoplasia: a variant of HNPCC? *Fam Cancer* 2001; 1: 101-105.
7. Menko FH, Kaspers GM, Meijer GA, Claes K, van Hagen JM, Gille JJ. A homozygous MSH6 mutation in a child with café-au-lait spots, oligodendroglioma and rectal cancer. *Fam Cancer* 2004; 3: 123-127.
8. Poley JW, Wagner A, Hoogmans MM, Menko FH, Tops C, Kros JM, Reddingius RE, Meijers-Heijboer H, Kuipers EJ, Dinjens WN; Rotterdam Initiative on Gastrointestinal Hereditary Tumors. Biallelic germline mutations of mismatch-repair genes: a possible cause for multiple pediatric malignancies. *Cancer* 2007; 109: 2349-2356.
9. Hegde MR, Chong B, Blazo ME, Chin LH, Ward PA, Chintagumpala MM, Kim JY, Plon SE, Richards CS. A homozygous mutation in MSH6 causes Turcot syndrome. *Clin Cancer Res* 2005; 11: 4689-4693.
10. Plaschke J, Linnebacher M, Kloor M, Gebert J, Cremer FW, Tinschert S, Aust DE, von Knebel Doeberitz M, Schackert HK. Compound heterozygosity for two MSH6 mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumor. *Eur J Hum Genet* 2006; 14: 561-566.
11. Ostergaard JR, Sunde L, Okkels H. Neurofibromatosis von Recklinghausen type I phenotype and early onset of cancers in siblings compound heterozygous for mutations in MSH6. *Am J Med Genet A* 2005; 139: 96-105.

Biliary tract cancer, familial clustering of

Synonym: including familial gallbladder cancer

Mode of inheritance: multifactor

Tumour features:

biliary tract cancer (including gallbladder)

Tumour features (possible):

pancreatic adenocarcinoma

Comment

A Spanish-Italian study demonstrated an association between a family history of gallbladder cancer and the development of this tumour in a relative (RR 13.9) [1]. Hemminki et al. [2] studied the occurrence of cancer in relatives of patients with liver or biliary tract cancers. The authors demonstrated a high risk for familial gallbladder cancer (SIR 5.21 [95% CI 2.07-10.80]) and for familial hepatocellular cancer (SIR 4.69 [95% CI 1.48-11.04]). For

gallbladder and hepatocellular cancer, maternal transmission appeared to be more prevalent. Gallbladder cancer was associated with pancreatic cancer (SIR 2.39 [95% CI 1.23-4.18]).

References

1. Fernandez E, La Vecchia C, D'Avanzo B, Negri E, Franceschi S. Family history and the risk of liver, gallbladder, and pancreatic cancer. *Cancer Epidemiol Biomarkers Prev* 1994; 3: 209-212.
2. Hemminki K, Li X. Familial liver and gall bladder cancer: a nationwide epidemiological study from Sweden. *Gut* 2003; 52: 592-596.

Birt-Hogg-Dubé syndrome

Synonym: fibrofolliculomas with trichodiscomas and acrochordons, including Hornstein-Knickenberg syndrome, perifollicular fibromatosis

Mode of inheritance: AD

OMIM number: 135150

Genes:

FLCN, mapped to 17p11.2

Tumour features:

acrochordons

fibrofolliculomas

perifollicular fibromas

trichodiscomas

Tumour features (possible):

chromophobe renal cell cancer

colon cancer

colorectal polyps

renal cell cancer, clear-cell

renal cell cancer, papillary

renal oncocytoma

thyroid cancer, medullary

Non-tumour features:

lung cysts

pneumothorax, spontaneous

Comment

This condition is characterized by the presence of 3 types of benign skin tumours: fibrofolliculomas, trichodiscomas and acrochordons [1-4], although its has been questioned whether acrochordons truly belong to this hereditary disorder [5]. Spontaneous pneumothorax and cystic lung disease is another feature of BHD [6].

In one large family with this disorder, medullary thyroid cancer was diagnosed in several relatives, 2 of them also presenting with skin tumours. It may have been a coincidental co-segregation of familial medullary thyroid cancer (see that entry) and Birt-

Hogg-Dubé syndrome. Benign and malignant adenomatous colon polyps have been reported in patients with this disorder and with what some consider to be a variant of Birt-Hogg-Dubé syndrome: Hornstein-Knickenberg syndrome, which is characterized by multiple perifollicular fibromas [7-10]. Renal tumours (single or multiple, unilateral or bilateral) of various histology have been observed in Birt-Hogg-Dubé syndrome: oncocytoma, chromophobe carcinoma and clear cell as well papillary renal cell carcinomas [11-13].

References

1. Birt AR, Hogg GR, Dubé WJ. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. *Arch Dermatol* 1977; 113: 1674-1677.
2. Weintraub R, Pinkus H. Multiple fibrofolliculomas (Birt-Hogg-Dubé) associated with a large connective tissue nevus. *J Cutan Pathol* 1977; 4: 298-299.
3. Bayrou O, Blanc F, Moulouguet I, Millet P, Garrel JB, Civatte J. Syndrome de Birt-Hogg-Dubé. fibrofolliculomes, trichodiscomes et acrochordons. *Ann Dermatol Venerol* 1990; 117: 37-41.
4. Cohen PR, Kurzrock R. Miscellaneous genodermatoses: Beckwith-Wiedemann syndrome, Birt- Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome, hereditary tylosis, incontinentia pigmenti, and supernumerary nipples. *Dermatol Clin* 1995; 13: 211-229.
5. De la Torre C, Ocampo C, Doval IG, Losada A, Cruces MJ. Acrochordons are not a component of the Birt-Hogg-Dubé syndrome: does this syndrome exist? Case reports and review of the literature. *Am J Dermatopathol* 1999; 21: 369-374.
6. Toro JR, Pautler SE, Stewart L, Glenn GM, Weinreich M, Toure O, Wei MH, Schmidt LS, Davis L, Zbar B, Choyke P, Steinberg SM, Nguyen DM, Linehan WM. Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. *Am J Respir Crit Care Med* 2007; 175: 1044-1053.
7. Hornstein OP, Knickenberg M. Perifollicular fibromatosis cutis with polyps of the colon – a cutaneo-intestinal syndrome sui generis. *Arch Dermatol Res* 1975; 253: 161-175.
8. Hornstein OP. Generalized dermal perifollicular fibromas with polyps of the colon. *Hum Genet* 1976; 33: 193-197.
9. Simon M Jr, Hornstein OP, Haneke E. Perifollikulare fibromatose. Eine kutane paraneoplasie? *Hautartz* 1982; 33: 481-483.
10. McKenna DB, Barry-Walsh C, Leader M, Murphy GM. Multiple perifollicular fibromas. *J Eur Acad Dermatol Venerol* 1999; 12: 234-237.
11. Toro JR, Glenn G, Duray P, Darling T, Weirich G, Zbar B, Linehan M, Turner ML. Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia. *Arch Dermatol* 1999; 135: 1195-1202.
12. Leter EM, Koopmans AK, Gille JJ, van Os TA, Vitztoz GG, David EF, Jaspars EH, Postmus PE, van Moorselaar RJ, Craanen ME, Starink TM, Menko FH. Birt-Hogg-Dubé syndrome: clinical and genetic studies of 20 families. *J Invest Dermatol* 2008; 128: 45-49.
13. Schmidt LS, Nickerson ML, Warren MB, Glenn GM, Toro JR, Merino MJ, Turner ML, Choyke PL, Sharma N, Peterson J, Morrison P, Maher ER, Walther MM, Zbar B, Linehan WM. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. *Am J Hum Genet* 2005; 76: 1023-1033.

Bladder, ureter, renal pyelum cancer, familial clustering of

Mode of inheritance: multifactor?

Genes: many low penetrant gene mutations have been reported, we do not list them separately here

Tumour features:

renal pyelum cancer

ureter cancer

urinary bladder cancer

Non-tumour features (possible):

t(5;20)(p15;q11) (constitutional)

Comment

Familial clustering of bladder cancer has been reported [1-5] and may occur in approximately 4% of cases [6]. Kantor et al. [6] demonstrated that having an affected first-degree relative increases the risk of bladder cancer. These authors reported relative risks of 2.7, 1.7 and 1.3 depending on the age at diagnosis of the tumour: below age 45, ages 45-64 and 65 and older, respectively. Cigarette smoking in the setting of a family history of bladder cancer was shown to strongly increase the risk of developing this tumour. Relative risks of up to 28.1 in heavy smokers (60 + cigarettes/day) were calculated as compared to a RR of 2.1 in heavy smokers with a negative family history. Non-smokers with a positive family history still had a RR of 1.5 and this observation of a familial component independent of smoking was supported by the findings of Kramer et al. [7], who reported a RR of 1.8 for a similar group. Piper et al. [8] found bladder or renal cancer in first-degree relatives not to be a risk factor for bladder cancer in young women (<50 years). A family history of cancer in general has been reported to be a risk factor in the development of bladder cancer [2].

Having blood type A or HLA types Cw4 and B5 increases the risk of developing this tumour [9]. Inherited variation in the metabolism of (pro)carcinogens, related to smoking and other environmental exposures, also influences the risk of bladder cancer, e.g. activities of glutathione-S-transferase, N-acetyltransferase and those of the cytochrome P450 group [10-13]. Also, certain alleles of the Hras1 minisatellite locus are associated with an increased tumour risk at this anatomical site [14]. More mutations have been reported, not listed in this brief overview. A small number of published families suggest the existence of a rare autosomal dominant predisposition to urinary tract cancer [3, 5, 15]. Familial clustering of transitional cell carcinomas (TCC) at different sites of the urinary tract has been observed [5, 16, 17], including familial cancer of the ureter [18]. A germline translocation

(5;20)(p15;q11) has been observed in a 29-year-old man with TCC bladder cancer. His mother had been diagnosed with a similar tumour (she was not karyotyped) [19].

References

1. Lynch HT, Kimberling WJ, Lynch JF, Brennan K. Familial bladder cancer in an oncology clinic. *Cancer Genet Cytogenet* 1987; 27: 161-165.
2. Bravo MP, Del Rey-Calero J, Conde M. Risk factors of bladder cancer in Spain. *Neoplasma* 1987; 34: 633-637.
3. Lynch HT, Walzak MP, Fried R, Domina AH, Lynch JF. Familial factors in bladder carcinoma. *J Urol* 1979; 122: 458-461.
4. Purtilo DT, McCarthy B, Yang JP, Friedell GH. Familial urinary bladder cancer. *Semin Oncol* 1979; 6: 254-256.
5. Kiemeny LA, Schoenberg M. Familial transitional cell carcinoma. *J Urol* 1996; 156: 867-872.
6. Kantor AF, Hartge P, Hoover RN, Fraumeni JF Jr. Familial and environmental interactions in bladder cancer risk. *Int J Cancer* 1985; 35: 703-706.
7. Kramer AA, Graham S, Burnett WS, Nasca P. Familial aggregation of bladder cancer stratified by smoking status. *Epidemiology* 1991; 2: 145-148.
8. Piper JM, Matanoski GM, Tonascia J. Bladder cancer in young women. *Am J Epidemiol* 1986; 123: 1033-1042.
9. Herring DW, Cartwright RA, Williams DD. Genetic associations of transitional cell carcinoma. *Br J Urol* 1979; 51: 73-77.
10. Maher ER. Genetics of urological cancers. *Br Med Bull* 1994; 50: 698-707.
11. Branch RA, Chern HD, Adedoyin A, Romkes-Sparks M, Lesnick TG, Persad R, Wilkinson GR, Fleming CM, Dickinson AJ, Sibley G, et al. The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors. *Pharmacogenetics* 1995; 5: S97-S102.
12. Ross RK, Jones PA, Yu MC. Bladder cancer epidemiology and pathogenesis. *Semin Oncol* 1996; 23: 536-545.
13. Schulte PA. The role of genetic factors in bladder cancer. *Cancer Detect Prev* 1988; 11: 379-388.
14. Krontiris TG, Devlin B, Karp DD, Robert NJ, Risch N. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. *N Engl J Med* 1993; 329: 517-523.
15. Mahboubi AO, Ahlvin RC, Mahboubi EO. Familial aggregation of urothelial carcinoma. *J Urol* 1981; 126: 691-692.
16. Orphali SL, Shols GW, Hagedwood J, Tesluk H, Palmer JM. Familial transitional cell carcinoma of renal pelvis and upper ureter. *Urology* 1986; 5: 394-396.
17. Kiemeny LA, Moret NC, Witjes JA, Schoenberg MP, Tulinius H. Familial transitional cell carcinoma among the population of Iceland. *J Urol* 1997; 157: 1649-1651.
18. Burkland CE, Juzek RH. Familial, occurrence of carcinoma of the ureter. *J Urol* 1966; 96: 697-701.
19. Schoenberg M, Kiemeny L, Walsh PC, Griffin CA, Sidransky D. Germline translocation t(5;20)(p15;q11) and familial transitional cell carcinoma. *J Urol* 1996; 155: 1035-1036.

Bloom syndrome

Mode of inheritance: AR

OMIM number: 210900

Genes:

BLM, mapped to 15q26.1

Tumour features:

breast cancer
cervical cancer
colon cancer
gastric cancer
hepatocellular cancer
laryngeal cancer
leukaemia, acute lymphoblastic (ALL)
leukaemia, acute myeloid (AML, including ANLL)
lymphoma, malignant (non-Hodgkin's and/or Hodgkin's)
oral cancer
skin cancer, basal cell
Wilms' tumour (nephroblastoma)

Tumour features (possible):

colorectal adenomatous polyps
external auditory canal cancer
medulloblastoma
myelodysplastic syndrome (MDS)
osteosarcoma
skin cancer, squamous cell
vaginal cancer

Non-tumour features:

clinodactyly
growth deficiency
hyperpigmentation of the skin
hypopigmentation of the skin
immunodeficiency
increased chromosomal breakage
increased sister chromatid exchange
long small facies
mutagen sensitivity, increased
UV hypersensitivity
UV radiation sensitivity, increased

Non-tumour features (possible):

bone marrow monosomy 7 karyotype

Comment

Clinical features of this disorder are [1-4]: short stature, dolichocephaly, excessive number of neoplasms (see below), characteristic facies (malar hypoplasia, prominent nose, small mandible, protuberant prominent ears), UV hypersensitivity of the skin (lesions appear mainly in the face and back of hand/forearms), patchy hyperpigmentation (café-au-lait spots) and areas of hypopigmentation of the skin (predominantly on the trunk), variable degree of vomiting and diarrhoea during infancy, diabetes mellitus, azoospermia and early menopause, immunodeficiency, average to low-average intelligence, sometimes mental retardation. Cytogenetic studies show increased sister-chromatid exchange and excessive number of chromatid gaps and breaks. Neoplasms reported in Bloom syndrome (in decreasing frequency): non-Hodgkin's lymphoma, skin cancer (predominantly basal cell type),

acute lymphocytic and acute myelocytic leukaemia, breast cancer, colon (diagnosed as early as age 16 [5]) and rectal cancer, oesophageal cancer, tongue cancer, laryngeal cancer, cervical cancer and endometrial cancer, tongue cancer, external auditory canal cancer, Wilms' tumour, osteogenic sarcoma, medulloblastoma and meningioma, tonsillar cancer, retinoblastoma and myelodysplastic syndrome (associated with monosomy 7 [6]). Wang et al. [7] reported a 37-year-old man with ulcerative colitis complicated by colon cancer. Lowy et al. observed colonic polyposis in a Bloom syndrome patient [8]. More recently hepatocellular cancer and vaginal cancer were reported [9, 10].

References

1. German J. Bloom's syndrome. *Dermatol Clin* 1995; 13: 7-18.
2. German J. Bloom's syndrome. XX. The first 100 cancers. *Cancer Genet Cytogenet* 1997; 93: 100-106.
3. German J, Passarge E. Bloom's syndrome. XII. Report from the Registry for 1987. *Clin Genet* 1989; 35: 57-69.
4. Berkower AS, Biller HF. Head and neck cancer associated with Bloom's syndrome. *Laryngoscope* 1988; 98: 746-748.
5. Balci S, Aktas D. Mucinous carcinoma of the colon in a 16-year-old Turkish boy with Bloom syndrome: cytogenetic, histopathologic, TP53 gene and protein expression studies. *Cancer Genet Cytogenet* 1999; 111: 45-48.
6. Aktas D, Koc A, Boduroglu K, Hicsonmez G, Tuncbilek E. Myelodysplastic syndrome associated with monosomy 7 in a child with Bloom syndrome. *Cancer Genet Cytogenet* 2000; 116: 44-46.
7. Wang J, German J, Ashby K, French SW. Ulcerative colitis complicated by dysplasia-adenoma-carcinoma in a man with Bloom's syndrome. *J Clin Gastroenterol* 1999; 28: 380-382.
8. Lowy AM, Kordich JJ, Gismondi V, Varesco L, Blough RI, Groden J. Numerous colonic adenomas in an individual with Bloom's syndrome. *Gastroenterology* 2001; 121: 435-439.
9. Jain D, Hui P, McNamara J, Schwartz D, German J, Reyes-Múgica M. Bloom syndrome in sibs: first reports of hepatocellular carcinoma and Wilms tumor with documented anaplasia and nephrogenic rests. *Pediatr Dev Pathol* 2001; 4: 585-589.
10. Goudge CS, Downs LS, Judson PL, Argenta PA. Stage II squamous cell carcinoma of the vagina in a patient with Bloom syndrome: a case report. *J Reprod Med* 2007; 52: 557-559.

Blue rubber bleb nevus syndrome

Synonym: Bean syndrome

Mode of inheritance: AD/spor

OMIM number: 112200

Tumour features:

gastrointestinal polypoid haemangioma
hepatic haemangioma
joint capsules, haemangioma in
lung haemangioma
splenic haemangioma
subcutaneous haemangioma

Tumour features (possible):

leukaemia, chronic lymphocytic (CLL)

medulloblastoma

renal cell cancer

Non-tumour features:

cutaneous nevi, haemangiomatous (blue rubber blebs)

Comment

The hallmarks of this disease are the presence of multiple bladder-like haemangiomas (blue rubber blebs) on the skin, especially on the trunk and arms. The intestinal polypous haemangiomas may cause bleeding. Haemangiomas may be found in a wide range of tissues (spleen, lungs, joint capsules etc.) [1-3]. Chronic lymphocytic leukaemia (at age 66) and renal cell cancer (at age 57) were reported in a male with this disorder [4]. Medulloblastoma was reported in a 21-year old affected woman [5]. This condition may be identical to familial venous malformation syndrome.

References

1. Laugier P. Blue rubber bleb nevus (author's transl). *Ann Dermatol Venereol* 1978; 105: 729-731.
2. Munkvad M. Blue rubber bleb nevus syndrome. *Dermatologica* 1983; 167: 307-309.
3. Morris SJ, Kaplan SR, Ballan K, Tedesco FJ. Blue rubber-bleb nevus syndrome. *JAMA* 1978; 239: 1887.
4. Hoffman T, Chasko S, Safai B. Association of blue rubber bleb nevus syndrome with chronic lymphocytic leukemia and hypernephroma. *Johns Hopkins Med J* 1978; 142: 91-94.
5. Rice JS, Fischer DS. Blue rubber-bleb nevus syndrome. Generalized cavernous hemangiomatosis or venous hamartoma with medulloblastoma of the cerebellum: case report and review of the literature. *Arch Dermatol* 1962; 86: 503-511.

Bone dysplasia with malignant change, hereditary

Synonym: hereditary bone dysplasia with malignant fibrous histiocyoma, diaphyseal medullary stenosis with malignant fibrous histiocyoma, DMS-MFH

Mode of inheritance: AD

OMIM number: 112250

Genes:

DMSMFH/BDMF, mapped to 9p21-p22

Tumour features:

bone, malignant fibrous histiocyoma of the

Non-tumour features:

cataract

skeletal dysplasia

Comment

This disorder is characterized by bone dysplasia presenting with diaphyseal medullary stenosis of

bone with overlying cortical bone thickening. The epiphysis is not affected. The bone changes may not appear until the 3rd or 4th decade of life. Other features are fractures after minimal trauma and malignant transformation (typically in 2nd-5th decade). The neoplasms were originally classified as fibrosarcomas, but later reclassified as malignant fibrous histiocyomas. Approximately 35% of gene carriers develop these malignant tumours. Early-onset cataract was documented in some of the patients and mental retardation was seen in a minority of cases [1, 2]. This syndrome maps to 9p21-22 [3, 4].

References

1. Hardcastle P, Nade S, Arnold W. Hereditary bone dysplasia with malignant change. Report of three families. *J Bone Joint Surg Am* 1986; 68: 1079-1089.
2. Miyake M, Tateishi U, Maeda T, Arai Y, Hasegawa T, Sugimura K. Diaphyseal medullary stenosis with pleomorphic malignant fibrous histiocyoma of the bone: 99mTc hydroxymethylenediphosphonate and 201Tl chloride scintigraphy findings. *Ann Nucl Med* 2006; 20: 233-236.
3. Martignetti JA, Desnick RJ, Aliprandis E, Norton KI, Hardcastle P, Nade S, Gelb BD. Diaphyseal medullary stenosis with malignant fibrous histiocyoma: a hereditary bone dysplasia/cancer syndrome maps to 9p21-22. *Am J Hum Genet* 1999; 64: 801-807.
4. Martignetti JA, Gelb BD, Pierce H, Picci P, Desnick RJ. Malignant fibrous histiocyoma: inherited and sporadic forms have loss of heterozygosity at chromosome bands 9p21-22-evidence for a common genetic defect. *Genes Chromosomes Cancer* 2000; 27: 191-195.

Brain tumours, familial clustering of

Synonym: including familial medulloblastoma

Mode of inheritance: multifact?/AR?/AD?

OMIM number: 137800

Genes:

CYP2D6, mapped to 22q13.1

GSTM1, mapped to 1p13.3

GSTT1, mapped to 22q11.2

TP53, mapped to 17p13.1

Tumour features:

astrocytoma

brain, sarcoma of the

choroid plexus papilloma

ependymoma

Ewing sarcoma

glioblastoma (multiforme)

glioma of the brain

medulloblastoma

meningioma

prostate cancer

Tumour features (possible):

breast cancer
colon cancer
gastric cancer
Hodgkin's disease
leukaemia
malignant melanoma, cutaneous

Comment

Familial occurrence of brain tumours has predominantly been reported in sibs, but in some cases the tumours have been found in successive generations [1-5]. The most frequent tumours in these clusters are astrocytoma, medulloblastoma [6, 7] and glioblastoma [8]. Less frequently, choroid plexus papillomas [9], ependymomas [10] and sarcomas [11] have been reported. Figures on the percentage of brain tumours that are familial are rare. Estimates for astrocytomas range from less than 1 to 14% [12]. In the Swedish Family-Cancer Database, which included 2060 childhood brain tumours, 1.3% of brain tumour patients had a parent with nervous system cancer. Some studies conclude that a family history of brain tumours or cancer in general does not significantly contribute to glioma risk in adults and brain tumour risk in children [13-17]. Others found that the occurrence of childhood brain tumour is associated with an increased risk of developing central nervous system tumours, leukaemia and childhood tumours in relatives [18-20]. One study found a particularly strong association between parental meningioma and brain astrocytoma in the offspring [20]. Malmer et al. [26] studied cancer risk in the first-degree relatives of Swedish astrocytoma patients and found an increased risk for astrocytomas (relative risk 2.1) but not for other primary brain tumours in these relatives.

Hill et al. reported that in individuals with a family history of a brain cancer or a brain tumour, risk of glioma was 1.6 and 3.0, respectively, in comparison with those without such family histories. Increased risks were also reported for a family history of stomach (RR 2.2), colon (RR 1.4), or prostate cancer (RR 2.1) or Hodgkin's disease (RR 2.4) [21]. In another paper they reported that risk of meningioma was increased among those with a family history of a benign brain tumour (RR 4.5) or melanoma (RR 4.2). A family history of breast cancer was associated with an elevated meningioma risk among participants aged 18 to 49 years (RR 3.9) but a reduced risk among older individuals [22].

In general, the familial clustering of gliomas may be associated with a range of congenital malformations and is a genetically heterogeneous group [2]. Relatives

of patients with Ewing sarcoma or prostate cancer are at increased risk of developing brain tumours [23, 24]. Significantly more colon cancer was observed in first-degree relatives of children with brain tumours, although absolute numbers were small [25]. Interestingly, another study reported a significant decrease in colon (and breast) cancer risk for first-degree relatives of astrocytoma patients [26]. Certain variants of enzymes involved in (pro)carcinogen metabolism have been found to be associated with an increased risk of astrocytomas and meningiomas, e.g. GSTT1, GSTM1 and CYP2D6 [27]. A small fraction of familial clustering of gliomas may be attributed to germline TP53 mutations [28-31].

References

1. Tijssen CC, Halprin MR, Endtz LJ. Familial brain tumours. Martinus Nijhoff Publishers, Hague 1982.
2. Viegge P, Gerhard L, Nahser HC. Familial glioma: occurrence within the "familial cancer syndrome" and systemic malformations. *J Neurol* 1987; 234: 220-232.
3. Ikizler Y, van Meyel DJ, Ramsey DA, Abdallah GL, Allaster RM, Macdonald DR, Cavenee WK, Cairncross JG. Gliomas in families. *Can J Neurol Sci* 1992; 19: 492-497.
4. Isamat F, Miranda AM, Bartumeus F, Prat J. Genetic implications of familial brain tumors. *J Neurosurg* 1974; 41: 573-575.
5. Armstrong RM, Hanson CW. Familial gliomas. *Neurology* 1969; 19: 1061-1063.
6. Hung KL, Wu CM, Huang JS, How SW. Familial medulloblastoma in siblings: report in one family and review of the literature. *Surg Neurol* 1990; 33: 341-346.
7. Moschovi M, Sotiris Y, Prodromou N, Tsangaris GT, Constantinidou Van-Vliet C, Kalpini-Mavrou A, Tzortzidou-Stathopoulou F. Familial medulloblastoma. *Pediatr Hemat Oncol* 1998; 15: 421-424.
8. Chemke J, Katznelson D, Zucker G. Familial glioblastoma multiforme without neurofibromatosis. *Am J Med Genet* 1985; 21: 731-735.
9. Zwetsloot CP, Kros JM, Paz y Geuze HD. Familial occurrence of tumours of the choroid plexus. *J Med Genet* 1991; 28: 492-494.
10. Nijssen PC, Deprez RH, Tijssen CC, Hagemeijer A, Arnoldus EP, Teepen JL, Holl R, Niermeyer ME. Familial anaplastic ependymoma: evidence of loss of chromosome 22 in tumour cells. *J Neurol Neurosurg Psychiatry* 1994; 57: 1245-1248.
11. Gainer JV Jr, Chou SM, Chadduck WM. Familial cerebral sarcomas. *Arch Neurol* 1975; 32: 665-668.
12. Kaufman DK, Kimmel DW, Parisi JE, Michels VV. A familial syndrome with cutaneous malignant melanoma and cerebral astrocytoma. *Neurology* 1993; 43: 1728-1731.
13. Giuffr  R, Liccardo G, Pastore FS, Spallone A, Vagnozzi R. Potential risk factors for brain tumors in children. An analysis of 200 cases. *Childs Nerv Syst* 1990; 6: 8-12.
14. Gold EB, Leviton A, Lopez R, Austin DF, Gilles FH, Hedley-Whyte ET, Kolonel LN, Lyon JL, Swanson GM, Weiss NS, et al. The role of family history in risk of childhood brain tumors. *Cancer* 1994; 73: 1302-1311.
15. Cicuttini FM, Hurley SF, Forbes A, Donnan GA, Salzberg M, Giles GG, McNeil JJ. Association of adult glioma with medical conditions, family and reproductive history. *Int J Cancer* 1997; 71: 203-207.

16. Wrensch M, Lee MM, Miike R, Newman B, Barger G, Davis R, Wiencke J, Neuhaus J. Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. *Am J Epidemiol* 1997; 145: 581-593.
17. Kuijten RR, Strom SS, Rorke LB, Boesel CP, Buckley JD, Meadows AT, Bunin GR. Family history of cancer and seizures in young children with brain tumors: a report from the Childrens Cancer Group (United States and Canada). *Cancer Causes Control* 1993; 4: 455-464.
18. Farwell J, Flannery JT. Cancer in relatives of children with central-nervous-system neoplasms. *N Engl J Med* 1984; 311: 749-753.
19. Graf N, Breitenmoser M, Jobke A, Kaatsch P. Malignancies in families of children with cancer. *Klin Padiatr* 1990; 202: 282-287.
20. Hemminki K, Li X, Vaittinen P, Dong C. Cancers in the first-degree relatives of children with brain tumours. *Br J Cancer* 2000; 83: 407-411.
21. Hill DA, Inskip PD, Shapiro WR, Selker RG, Fine HA, Black PM, Linet MS. Cancer in first-degree relatives and risk of glioma in adults. *Cancer Epidemiol Biomarkers Prev* 2003; 12: 1443-1448.
22. Hill DA, Linet MS, Black PM, Fine HA, Selker RG, Shapiro WR, Inskip PD. Meningioma and schwannoma risk in adults in relation to family history of cancer. *Neuro Oncol* 2004; 6: 274-280.
23. Isaacs SD, Kiemeny LA, Boffee-Bonnie A, Beaty TH, Walsh PC. Risk of cancer in relatives of prostate cancer probands. *J Natl Cancer Inst* 1995; 87: 991-996.
24. Novakovic B, Goldstein AM, Wexler LH, Tucker MA. Increased risk for neuroectodermal tumors and stomach cancer in relatives of patients with Ewing's sarcoma family of tumors. *J Natl Cancer Inst* 1994; 86: 1702-1706.
25. Bondy ML, Lustbader ED, Buffler PA, Schull WJ, Hardy RJ, Strong LC. Genetic epidemiology of childhood brain tumors. *Genet Epidemiol* 1991; 8: 253-267.
26. Malmer B, Grönberg H, Bergenheim AT, Lenner P, Henriksson R. Familial aggregation of astrocytoma in northern Sweden: an epidemiological cohort study. *Int J Cancer* 1999; 81: 366-370.
27. Elexpuru-Camiruaga J, Buxton N, Kandula V, Dias PS, Campbell D, McIntosh J, Broome J, Jones P, Inskip A, Alldersea J, Fryer AA, Strange RC. Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione S-transferase (GSTT1 and GSTM1) and Cytochrome P-450 (CYP2D6) loci. *Cancer Res* 1995; 55: 4237-4239.
28. Li YJ, Sanson M, Hoang-Xuan K, Delattre JY, Poisson M, Thomas G, Hamelin R. Incidence of germ-line p53 mutations in patients with gliomas. *Int J Cancer* 1995; 64: 383-387.
29. Kyritsis AP, Bondy ML, Xiao M, Berman EL, Cunningham JE, Lee PS, Levin VA, Saya H. Germline p53 gene mutations in subsets of glioma patients. *J Natl Cancer Inst* 1994; 86: 344-349.
30. Lübke J, von Ammon K, Watanabe K, Hegi ME, Kleihues P. Familial brain tumour syndrome associated with a p53 germline deletion of codon 236. *Brain Pathol* 1995; 5: 15-23.
31. Chen P, Iavarone A, Fick J, Edwards M, Prados M, Israel MA. Constitutional p53 mutations associated with brain tumors in young adults. *Cancer Genet Cytogenet* 1995; 82: 106-115.

Breast cancer, familial clustering of

Mode of inheritance: multifactorial

OMIM number: 114480

Genes many low penetrant gene mutations have been reported, we do not list them separately here

Tumour features:

breast cancer

colorectal cancer

endometrial cancer

ovarian cancer (i.e. epithelial origin)

prostate cancer

Non-tumour features:

breast, proliferative disease

mutagen sensitivity, increased

Comment

Given the high risk of breast cancer in women [1], familial occurrence of breast cancer is not rare. A family history of breast cancer has been reported in 14 to 30% of female breast cancer patients [2, 3]. Familial male breast cancer is rare [4-6]. Having a relative with breast cancer is one of the strongest risk factors for this tumour [7-10]. A RR of 34.7 of developing breast cancer has been reported in monozygotic twins of women in whom breast cancer had occurred before age 35 [11]. In general, the risk of breast cancer in relatives does not appear to depend heavily on the gender of their affected family member [12-15]. Compared with the general population, breast cancer is also found more frequently in women with family history of ovarian, endometrial, colorectal and/or prostate cancer and vice versa [16-24]. One study reported a RR of 5.6 for parotid cancer in first-degree relatives of breast cancer patients [25].

Depending on the number of affected relatives, the degree of kinship and the age at onset of the tumours, the empirical risk of developing breast cancer in a female relative may be close to 50% (even higher if she already has children with breast cancer). Several models have been developed to estimate breast cancer risk in a specific family situation. Those by Gail et al. [26-30], focussing on white females who are being examined annually, and by Claus et al. [21, 31, 32] are the ones most widely used in clinical practice. Users should be aware of the specific limitations of these models [33]. For example, the risk tables may need to be adapted for use in different countries and or ethnic groups to account for differences in genetic background and exogenous risk factors [34]. The Claus model includes first- and second-degree relatives, as opposed to the Gail model, which looks at first-degree relatives only. However, the latter method also takes into account the risk factors of age at menarche, age at first live birth and number of previous biopsies.

Given a positive or negative family history of breast cancer, other known risk factors may differ in their contribution to overall risk. Colditz et al. [35] reported on an adverse effect of first pregnancy among women with a family history of breast cancer that was

approximately 50% greater in magnitude than among women without a family history. Past use of oral contraceptives and use of postmenopausal hormones and history of benign breast disease showed similar relative risks between the two groups. Sellers et al. concluded the same with regard to hormone replacement therapy in women with a family history of breast cancer [36]. However, with respect to benign breast disease, Dupont et al. [37] found that fibroadenomas have an increased effect on breast cancer risk in patients with a family history of breast cancer compared to patients without a family history of breast cancer. In addition, Skolnick et al. [38] analyzed families with a clustering of breast cancer and suggested that genetic susceptibility may cause both proliferative benign breast disease and breast cancer in those kindreds. Among women aged 30-49 years, a family history of breast cancer was associated with an increased risk of ductal carcinoma-in-situ (DCIS), and among those aged 50 and older it was associated with an increased risk of both DCIS and invasive breast cancer [39]. Egan et al. [40] demonstrated a stronger inverse association of high parity with breast cancer risk in women who reported first-degree relatives with breast cancer compared with women who did not have affected first-degree relatives. In a study by Schouten et al. [41], family history of breast cancer was not correlated with survival.

Chromosomes of breast cancer patients (and some of their unaffected relatives) with a family history of breast cancer are more sensitive to the action of the mutagen bleomycin compared with sporadic breast cancer patients [42], hinting at the involvement of genes responsible for DNA repair.

References

1. Feuer EJ, Wun LM, Boring CC, Flanders WD, Timmel MJ, Tong T. The lifetime risk of developing breast cancer. *J Natl Cancer Inst* 1993; 85: 892-897.
2. Bürki N, Gencik A, Torhorst JK, Weber W, Müller H. Familial and histological analyses of 138 breast cancer patients. *Breast Cancer Res Treat* 1987; 10: 159-167.
3. Lynch HT, Lynch JF. Breast cancer genetics in an oncology clinic: 328 consecutive patients. *Cancer Genet Cytogenet* 1986; 22: 369-371.
4. Demeter JG, Waterman NG, Verdi GD. Familial male breast carcinoma. *Cancer* 1990; 65: 2342-2343.
5. Kozak FK, Hall JG, Baird PA. Familial breast cancer in males. A case report and review of the literature. *Cancer* 1986; 58: 2736-2739.
6. Everson RB, Fraumeni JF Jr, Wilson RE, Li FP, Fishman J, Stout D, Norris HJ. Familial male breast cancer. *Lancet* 1976; 1: 9-12.
7. Vogel VG, Yeomans A, Higginbotham E. Clinical management of women at increased risk for breast cancer. *Breast Cancer Res Treat* 1993; 28: 195-210.
8. Henderson IC. Risk factors for breast cancer development. *Cancer* 1993; 71 (6 Suppl): 2127-2140.
9. Hulka BS, Stark AT. Breast cancer: cause and prevention. *Lancet* 1995; 346: 883-887.
10. Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN. Proportion of breast cancer cases in the United States explained by well-established risk factors. *J Natl Cancer Inst* 1995; 87: 1681-1685.
11. Swerdlow AJ, De Stavola BL, Swanwick MA, Maconochie NE. Risks of breast and testicular cancers in young adult twins in England and Wales: evidence on prenatal and genetic aetiology. *Lancet* 1997; 350: 1723-1728.
12. Anderson DE, Badzioch MD. Breast cancer risks in relatives of male breast cancer patients. *J Natl Cancer Inst* 1992; 84: 1114-1117.
13. Olsson H, Andersson H, Johansson O, Möller TR, Kristofferson U, Wenngren E. Population-based cohort investigations of the risk for malignant tumors in first-degree relatives and wives of men with breast cancer. *Cancer* 1993; 71: 1273-1278.
14. Rosenblatt KA, Thomas DB, McTiernan A, Austin MA, Stalsberg H, Stemhagen A, Thompson WD, Curnen MG, Satariano W, Austin DF, et al. Breast cancer in men: aspects of familial aggregation. *J Natl Cancer Inst* 1991; 83: 849-854.
15. Lenfant-Pejovic MH, Mlika-Cabanne N, Bouchardy C, Auquier A. Risk factors for male breast cancer: a franco-swiss case-control study. *Int J Cancer* 1990; 45: 661-665.
16. Schildkraut JM, Risch N, Thompson WD. Evaluating genetic association among ovarian, breast, and endometrial cancer: evidence for a breast/ovarian cancer relationship. *Am J Hum Genet* 1989; 45: 521-529.
17. Anderson DE, Badzioch MD. Familial breast cancer risks. Effects of prostate and other cancers. *Cancer* 1993; 72: 114-119.
18. Thompson WD. Genetic epidemiology of breast cancer. *Cancer* 1994; 74: 279-287.
19. Tulinius H, Olafsdottir GH, Sigvaldason H, Tryggvadóttir L, Bjarnadottir K. Neoplastic diseases in families of breast cancer patients. *J Med Genet* 1994; 31: 618-621.
20. Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H. Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. *BMJ* 1992; 305: 855-857.
21. Claus EB, Risch N, Thompson WD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. *Breast Cancer Res Treat* 1993; 28: 115-120.
22. Foulkes WD, Bolduc N, Lambert D, Ginsburg O, Olien L, Yandell DW, Tonin PN, Narod SA. Increased incidence of cancer in first degree relatives of women with double primary carcinomas of the breast and colon. *J Med Genet* 1996; 33: 534-539.
23. Goldgar DE, Easton DF, Cannon Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. *J Natl Cancer Inst* 1994; 86: 1600-1608.
24. Sutcliffe S, Pharoah PD, Easton DF, Ponder BA. Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer. *Int J Cancer* 2000; 87: 110-117.
25. van Nagell JR Jr, Gallion HH, Pavlik EJ, DePriest PD. Ovarian cancer screening. *Cancer* 1995; 76: 2086-2091.
26. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. *J Natl Cancer Inst* 1989; 81: 1879-1886.
27. Bondy ML, Lustbader ED, Halabi S, Ross E, Vogel VG. Validation of a breast cancer risk assessment model in women with a positive family history. *J Natl Cancer Inst* 1994; 8: 620-625.
28. Spiegelman D, Colditz GA, Hunter D, Hertzmark E. Validation of the Gail et al. model for predicting individual breast cancer risk. *J Natl Cancer Inst* 1994; 8: 600-607.
29. Gail MH, Benichou J. Validation studies on a model for breast cancer risk. *J Natl Cancer Inst* 1994; 8: 573-575.

30. Benichou J, Gail MH, Mulvihill JJ. Graphs to estimate an individualized risk of breast cancer. *J Clin Oncol* 1996; 14: 103-110.
31. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. *Am J Hum Genet* 1991; 48: 232-242.
32. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. *Cancer* 1993; 73: 643-651.
33. McGuigan KA, Ganz PA, Breat C. Agreement between breast cancer risk estimation methods. *J Natl Cancer Inst* 1996; 88: 1315-1317.
34. Becher H, ChangClaude J. Estimating disease risks for individuals with a given family history in different populations with an application to breast cancer. *Genet Epidemiol* 1996; 13: 229-242.
35. Colditz GA, Rosner BA, Speizer FE. Risk factors for breast cancer according to family history of breast cancer. For the Nurses' Health Study Research Group. *J Natl Cancer Inst* 1996; 88: 365-371.
36. Sellers TA, Mink PJ, Cerhan JR, Zheng W, Anderson KE, Kushi LH, Folsom AR. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. *Ann Intern Med* 1997; 127: 973-980.
37. Dupont WD, Page DL, Parl FF, Vnencak-Jones CL, Plummer WD Jr, Rados MS, Schuyler PA. Long-term risk of breast cancer in women with fibroadenoma. *N Engl J Med* 1994; 1: 10-15.
38. Skolnick MH, Cannon-Albright LA, Goldgar DE, Ward JH, Marshall CJ, Schumann GB, Hogle H, McWhorter WP, Wright EC, Tran TD, Bishop DT, Kushner JP, Eyre HJ. Inheritance of proliferative breast disease in breast cancer kindreds. *Science* 1990; 250: 1715-1720.
39. Kerlikowske K, Barclay J, Grady D, Sickles EA, Ernster V. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. *J Natl Cancer Inst* 1997; 89: 76-82.
40. Egan KM, Stampfer MJ, Rosner BA, Trichopoulos D, Newcomb PA, Trentham-Dietz A, Longnecker MP, Mittendorf R, Greenberg ER, Willett WC. Risk factors for breast cancer in women with a breast cancer family history. *Cancer Epidemiol Biomarkers Prev* 1998; 7: 359-364.
41. Schouten LJ, Hopperets PS, Jager JJ, Volovics L, Wils JA, Verbeek AL, Blijham GH. Prognostic significance of etiological risk factors in early breast cancer. *Breast Cancer Res Treat* 1997; 43: 217-223.
42. Jyothish B, Ankathil R, Chandini R, Vinodkumar B, Nayar GS, Roy DD, Madhavan J, Nair MK. DNA repair proficiency: a potential marker for identification of high risk members in breast cancer families. *Cancer Lett* 1998; 124: 9-13.

Byler disease

Synonym: PFIC-1, including Byler syndrome, progressive familial intrahepatic cholestasis

Mode of inheritance: AR

OMIM number: 211600

Genes:

FIC1/ATP8B1, mapped to 18q21

Tumour features:

hepatocellular cancer

Non-tumour features:

intrahepatic cholestasis

liver cirrhosis

Comment

Byler disease is characterized by intrahepatic cholestasis with an onset in infancy, leading to hepatic fibrosis and death. It was originally described in an Amish kindred. A similar disorder in children who are not members of that kindred is referred to as Byler syndrome. Both disorders are a subtype of progressive familial intrahepatic cholestasis (another type is Alagille s.) [1]. Bull et al. [2] concluded that Byler syndrome is heterogeneous from a clinicopathological point of view and is distinct from Byler disease (which has been linked to 18q).

Hepatocellular cancer may develop as a complication of Byler disease/syndrome [3-5].

References

1. Riely CA. Familial intrahepatic cholestatic syndromes. *Semin Liver Dis* 1987; 7: 119-133.
2. Bull LN, Carlton VE, Stricker NL, Baharloo S, DeYoung JA, Freimer NB, Magid MS, Kahn E, Markowitz J, DiCarlo FJ, McLoughlin L, Boyle JT, Dahms BB, Faught PR, Fitzgerald JF, Piccoli DA, Witzleben CL, O'Connell NC, Setchell KD, Agostini RM Jr, Kocoshis SA, Reyes J, Knisely AS. Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): evidence for heterogeneity. *Hepatology* 1997; 26: 155-164.
3. Quillin SP, Brink JA. Hepatoma complicating Byler disease. *AJR Am J Roentgenol* 1992; 159: 432-433.
4. Dahms BB. Hepatoma in familial cholestatic cirrhosis of childhood: its occurrence in twin brothers. *Arch Pathol Lab Med* 1979; 103: 30-33.
5. Ugarte N, Gonzalez-Crussi F. Hepatoma in siblings with progressive familial cholestatic cirrhosis of childhood. *Am J Clin Pathol* 1981; 76: 172-177.

Carcinoid, familial clustering of

Synonym: including carcinoid, intestinal

Mode of inheritance: multifactorial/AD?

OMIM number: 114900

Tumour features:

carcinoid of the lung

gastrointestinal carcinoid

Comment

Anderson reported a father and daughter both diagnosed with carcinoid of the appendix (at age 42 and 15 years, respectively) [1]. Moertel and Dockerty [2] reported on a 2-generation family with (multiple) intestinal carcinoids. One of the affected women developed breast cancer at age 53 while her mother had done so at age 47. Other tumours in that family included nasopharyngeal fibrosarcoma (age 5) and lung cancer (age 42), possibly suggesting Li-Fraumeni-

like syndrome (see that entry). Additional cases of familial intestinal carcinoids have been published [3-8]. An unknown proportion of these and other cases of familial carcinoid might very well be caused by germline mutations in *MEN1*, the gene associated with multiple endocrine neoplasia type 1. Perkins et al. [9] studied the family history of patients with carcinoid tumours of the lung and demonstrated that the proportion of distant metastasis in these patients was significantly higher among those with a positive family history of cancer (in general). Babovic-Vuksanovic et al. [10] studied the occurrence of cancer in first-degree relatives of 245 gastrointestinal carcinoid patients. For first-degree relatives, only the risk for carcinoid was increased ($p < 0.0001$, life-time risk 1.5%).

Oliveira et al. reported pulmonary carcinoid in two affected sibs and in a mother and daughter. No other signs of *MEN1* were present in these two families [11].

References

1. Anderson RE. A familial instance of appendiceal carcinoid. *Am J Surg* 1966; 111: 738-740.
2. Moertel CG, Dockerty MB. Familial occurrence of metastasizing carcinoid tumors. *Ann Intern Med* 1973; 78: 389-390.
3. Wale RJ, Williams JA, Beeley AH, Hughes ES. Familial occurrence in carcinoid tumours. *Aust N Z J Surg* 1983; 53: 325-328.
4. Methfessel HD, Bettzieche H, Methfessel G. Pregnancy and birth in appendix carcinoid tumor with familial disposition. *Zentralbl Gynakol* 1973; 95: 234-238.
5. Yeatman TJ, Sharp JV, Kimura AK. Can susceptibility to carcinoid tumors be inherited? *Cancer* 1989; 63: 390-393.
6. Kinova S, Duris I, Kovacova E, Stvrtina S, Galbavy S, Makaiova I. Malignant carcinoid in two brothers. *Bratisl Lek Listy* 2001; 102: 231-234.
7. Pal T, Liede A, Mitchell M, Calender A, Narod SA. Intestinal carcinoid tumours in a father and daughter. *Can J Gastroenterol* 2001; 15: 405-409.
8. Katdare MV, Fichera A, Heimann TM. Familial rectal carcinoid: report of two first-degree relatives with rectal carcinoid and review of the literature. *Tech Coloproctol* 2006; 10: 143-146.
9. Perkins P, Lee JR, Kemp BL, Cox JD. Carcinoid tumors of the lung and family history of cancer. *J Clin Epidemiol* 1997; 50: 705-709.
10. Babovic-Vuksanovic D, Constantinou CL, Rubin J, Rowland CM, Schaid DJ, Karnes PS. Familial occurrence of carcinoid tumors and association with other malignant neoplasms. *Cancer Epidemiol Biomarkers Prev* 1999; 8: 715-719.
11. Oliveira AM, Tazelaar HD, Wentzlaff KA, Kosugi NS, Hai N, Benson A, Miller DL, Yang P. Familial pulmonary carcinoid tumors. *Cancer* 2001; 91: 2104-2109.

Cardiac myxomas, familial clustering of

Mode of inheritance: AR?/AD?

OMIM number: 255960

Genes:

PRKAR1A, mapped to 17q22-q24

Tumour features:

cardiac myxoma

Comment

Familial cases of cardiac myxomas without further signs of Carney complex (see that entry) have been reported. A high rate of recurrence is associated with these cases [1]. Some families may carry a germline mutation in *PRKAR1A*, the gene involved in Carney complex [2, 3] and may be regarded as having a variant of that disorder.

References

1. Deshpande A, Kumar S, Chopra P. Recurrent, biatrial, familial cardiac myxomas. *Int J Cardiol* 1994; 47: 71-73.
2. Casey M, Vaughan CJ, He J, Hatcher CJ, Winter JM, Weremowicz S, Montgomery K, Kucherlapati R, Morton CC, Basson CT. Mutations in the protein kinase A α 1 regulatory subunit cause familial cardiac myxomas and Carney complex. *J Clin Invest* 2000; 106: R31-R38.
3. Kojima S, Sumiyoshi M, Watanabe Y, Suwa S, Matsumoto M, Nakata Y, Daida H. A Japanese case of familial cardiac myxoma associated with a mutation of the *PRKAR1A* gene. *Intern Med* 2005; 44: 607-610.

Cardiofaciocutaneous syndrome

Synonym: CFC

Mode of inheritance: sporadic (*de novo*)

OMIM number: 115150

Genes:

BRAF, mapped to 9q34

KRAS, mapped to 12p12.1

MEK1, mapped to 15q21

MEK2, mapped to 7q32

Tumour features:

hepatoblastoma

Tumour features (possible):

leukaemia, acute lymphoblastic (ALL)

rhabdomyosarcoma

Non-tumour features:

growth deficiency

heart, congenital defect

high forehead

hyperkeratosis

nasal bridge, depressed

palpebral fissures, downward slanting

woolly, sparse and friable hair

Comment

Hallmarks of CFC are a typical facies, congenital heart defects (predominantly pulmonary stenosis and ASD), growth failure and ectodermal anomalies. There is clinical and molecular overlap with Noonan syndrome and Costello syndrome. These disorders share disruption of the RAS/MAPK signalling pathway [1-3].

Van den Berg and Hennekam [4] reported a 5-year-old girl with CFC who was diagnosed with ALL and Makita reported another case [5]. Bisogno et al. [6] described a 20-month-old boy with CFC and an (embryonal) rhabdomyosarcoma. A hepatoblastoma was reported by Al-Rahawan [7].

References

1. Roberts A, Allanson J, Jadico SK, Kavamura MI, Noonan J, Opitz JM, Young T, Neri G. The cardiofaciocutaneous syndrome. *J Med Genet* 2006; 43: 833-842.
2. Narumi Y, Aoki Y, Niihori T, Neri G, Cavé H, Verloes A, Nava C, Kavamura MI, Okamoto N, Kurosawa K, Hennekam RC, Wilson LC, Gillesen-Kaesbach G, Wiczorek D, Lapunzina P, Ohashi H, Makita Y, Kondo I, Tsuchiya S, Ito E, Sameshima K, Kato K, Kure S, Matsubara Y. Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome. *Am J Med Genet A* 2007; 143: 799-807.
3. Nava C, Hanna N, Michot C, Pereira S, Pouvreau N, Niihori T, Aoki Y, Matsubara Y, Arveiler B, Lacombe D, Pasmant E, Parfait B, Baumann C, Héron D, Sigaudy S, Toutain A, Rio M, Goldenberg A, Leheup B, Verloes A, Cavé H. Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome. *J Med Genet* 2007; 44: 763-71.
4. van den Berg H, Hennekam RC. Acute lymphoblastic leukaemia in a patient with cardiofaciocutaneous syndrome. *J Med Genet* 1999; 36: 799-800.
5. Makita Y, Narumi Y, Yoshida M, Niihori T, Kure S, Fujieda K, Matsubara Y, Aoki Y. Leukemia in Cardio-facio-cutaneous (CFC) syndrome: a patient with a germline mutation in BRAF proto-oncogene. *J Pediatr Hematol Oncol* 2007; 29: 287-290.
6. Bisogno G, Murgia A, Mammi I, Strafella MS, Carli M. Rhabdomyosarcoma in a patient with cardio-facio-cutaneous syndrome. *J Pediatr Hematol Oncol* 1999; 21: 424-427.
7. Al-Rahawan MM, Chute DJ, Sol-Church K, Gripp KW, Stabley DL, McDaniel NL, Wilson WG, Waldron PE. Hepatoblastoma and heart transplantation in a patient with cardio-facio-cutaneous syndrome. *Am J Med Genet A* 2007; 143: 1481-1488.

Carney complex

Synonym: Carney syndrome, NAME syndrome, LAMB syndrome, familial myxoma syndrome

Mode of inheritance: AD

OMIM number: 160980

Genes:

CNC2, mapped to 2p15-p16

PRKAR1A, mapped to 17q22-q24

Tumour features:

adrenocortical disease, primary pigmented nodular (PPNAD)

breast myxoma

cardiac myxoma

ductal adenoma of the breast

ear canal myxoma

gastrointestinal schwannoma

pituitary gland tumour

schwannoma (neurilemmoma), peripheral nerve

schwannoma of the bone

schwannoma, psammomatous melanotic

schwannomas of the (posterior) spinal nerve roots

skin myxoma

testicular Sertoli-Leydig cell tumour

thyroid cancer, follicular

uterine leiomyoma

Tumour features (possible):

cervical mesenchymal tumour, atypical

colorectal adenomas

peripheral nerve tumour

pheochromocytoma

teratoma, benign cystic (dermoid cyst) of the ovary

vestibular schwannoma

Non-tumour features:

blue nevi,

café-au-lait spots

lentiginosis (spotty pigmentation)

lips, pigmentation of

oral mucosa, pigmentation of

Non-tumour features (possible):

oesophagus, Barrett's

Comment

More than 200 patients have been reported, half of them familial cases. Patients present with spotty multiple small brown to black macules (lentiginosis) on the skin and mucosae (67% of patients). Other pigmented lesions are café-au-lait spots, (epithelioid) blue nevi (19% of patients) and less frequently psammomatous melanotic schwannoma (neurilemmoma) [1]. Primary pigmented nodular adrenocortical disease (PPNAD) leading to Cushing's disease is also typical for the syndrome (found in 33% of patients).

A range of tumours can be found in Carney complex, including myxomas of the heart (in 30-61% of patients), breasts (20%), skin (37%) (of the eyelids in 25%) and external ear canal, testicular tumours (30%): testicular large cell calcifying Sertoli tumours (LCCST) and (less frequently) Leydig cell tumours, growth hormone producing pituitary adenomas (11%) and schwannomas of the upper GI tract, bone,

sympatic chain and the skin (as mentioned above) (total % schwannomas found in Carney complex: 11). Thyroid gland involvement is common (11%), ranging from follicular hyperplasia to cancer [2-4]. Nwokoro et al. [5] reported an affected 34-year-old woman from a Carney complex family, who in addition to features typical for this disorder also developed an atypical mesenchymal tumour of the cervix, neoplastic colonic polyps and Barrett's oesophagus.

There is evidence for genetic heterogeneity in Carney complex [4, 6-8]. In some families, linkage analysis may help in identifying affected relatives [9]. Germline mutations in the *PRKAR1A* gene have been detected in approximately 45% of Carney complex cases and can also be found in isolated familial myxoma and familial or isolated cases of PPNAD [10-12].

Criteria [4, 5, 13] – 2 of the following should be present:

- a) heart myxoma,
- b) breast myxoma (myxoid mammary fibroadenoma),
- c) skin myxoma,
- d) primary pigmented nodular adrenocortical disease,
- e) GH-secreting pituitary tumour,
- f) psammomatous melanotic schwannoma (PMS),
- g) ductal adenoma of the breast,
- h) large-cell calcifying Sertoli cell tumour of the testes (LCCST),
- i) spotty pigmentation if it is: multiple, present in a characteristic distribution (vermillion border of the lips, conjunctivae, external genitalia), not dependent on exposure to sunlight, and has histology consistent with lentigo rather than ephelide (freckle).

The presence of adrenocortical rest tumours is regarded as corroboratory evidence for the diagnosis [12].

Unfortunately, the name Carney syndrome is used by some to refer to the Carney complex, whereas others use it to refer to Carney triad, which is a completely different disorder.

References

1. Carney JA, Stratakis CA. Epithelioid blue nevus and psammomatous melanotic schwannoma: The unusual pigmented skin tumors of the Carney complex. *Semin Diagn Pathol* 1998; 15: 216-224.
2. Stratakis CA, Courcoutsakis NA, Abati A, Filie A, Doppman JL, Carney JA, Shawker T. Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex). *J Clin Endocrinol Metab* 1997; 82: 2037-2043.
3. Scherer K, Muller T, Stolz W, Aeber H, Schunkert H. A case of Carney complex. *Dtsch Med Wochenschr* 1998; 123: 972-976.
4. Stratakis CA, Carney JA, Lin JP, Papanicolaou DA, Karl M, Kastner DL, Pras E, Chrousos GP. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11

kindreds and linkage to the short arm of chromosome 2. *J Clin Invest* 1996; 97: 699-705.

5. Nwokoro NA, Korytkowski MT, Rose S, Gorin MB, Stadler MP, Witchel SF, Mulvihill JJ. Spectrum of malignancy and premalignancy in Carney syndrome. *Am J Med Genet* 1997; 73: 369-377.
6. Irvine AD, Armstrong DK, Bingham EA, Hadden DR, Nevin NC, Hughes AE. Evidence for a second genetic locus in Carney complex. *Br J Dermatol* 1998; 139: 572-576.
7. Milunsky J, Huang XL, Baldwin CT, Farah MG, Milunsky A. Evidence for genetic heterogeneity of the Carney complex (familial atrial myxoma syndromes). *Cancer Genet Cytogenet* 1998; 106: 173-176.
8. Stratakis CA, Kirschner LS, Taymans SE, Vaughan CJ, Hatcher CJ, Casey M, Carney JA, Basson CT. Genetic heterogeneity in Carney complex (OMIM 160980); contributions of loci at chromosomes 2 and 17 in its genetics [Abstract]. *Am J Hum Genet* 1999; 65.
9. Goldstein MM, Casey M, Carney JA, Basson CT. Molecular genetic diagnosis of the familial myxoma syndrome (Carney Complex). *Am J Med Genet* 1999; 86: 62-65.
10. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho Chung YS, Stratakis CA. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. *Nat Genet* 2000; 26: 89-92.
11. Casey M, Vaughan CJ, He J, Hatcher CJ, Winter JM, Weremowicz S, Montgomery K, Kucherlapati R, Morton CC, Basson CT. Mutations in the protein kinase A R1 alpha regulatory subunit cause familial cardiac myxomas and Carney complex. *J Clin Invest* 2000; 106: R31-R38.
12. Boikos SA, Stratakis CA. Carney complex: the first 20 years. *Curr Opin Oncol* 2007; 19: 24-29.
13. Stratakis CA, Kirschner LS, Carney JA. Carney complex: diagnosis and management of the complex of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas. *Am J Med Genet* 1998; 80: 183-185.

Carney triad

Synonym: Carney syndrome

Mode of inheritance: spor/multifactor

OMIM number: 604287

Tumour features:

adrenal adenoma
oesophageal leiomyoma
oesophageal stromal tumour
gastric leiomyosarcoma
gastric stromal sarcoma
paraganglioma, chromaffin (extra-adrenal pheochromocytoma)
pulmonary chondroma
small intestine, stromal tumour of

Tumour features (possible):

exostoses
leiomyosarcoma of the uterus
parathyroid adenoma
renal angiomyolipomas

Comment

The combination of gastric stromal sarcoma, extra-adrenal paraganglioma and pulmonary chondroma is referred to as the Carney triad. Carney reviewed the 79 reported cases [1]. Approximately 85% of Carney triad patients are female. Age of onset ranged from 7 to 48 years (82% diagnosed before age 30); 78% of the reported cases do not present with the complete triad but show only 2 of the 3 features, the paragangliomas being the least frequent component. Although most cases are sporadic, 2 patients have been reported each with a sibling who had one of the tumours of the triad [1]. Gastric stromal sarcomas are usually the presenting tumour. The name (epithelioid) leiomyosarcoma was used in the past to refer to these tumours, but smooth muscle markers have not been identified in all cases; hence the change to 'stromal sarcomas'. The chondromas (diagnosed between 12 and 49 years) are multiple unilateral in 24% and bilateral in 13% of cases and may be recognized more than 15 years earlier and more than 20 years later than the leiomyosarcomas. After surgery for the chondromas, one or more new tumours developed in 56% of patients. The paragangliomas (diagnosed between age 12 to 48 years) are generally catecholamine secreting; they are present in multiple sites in 22% and may undergo malignant change. Silent adrenocortical adenomas were present in 13% of the patients and are considered part of the disorder. Other tumours observed were: oesophageal leiomyoma and stromal tumour, duodenal (multiple) stromal tumours, uterine leiomyosarcoma, bony exostosis, renal angiomyolipoma, parathyroid adenomas, gluteal myoma [1-7].

Unfortunately, the name Carney syndrome is used by some to refer to the Carney triad, whereas others use it to refer to Carney complex (or LAMB or NAME syndrome), which is a completely different disorder.

References

1. Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. *Mayo Clin Proc* 1999; 74: 543-552.
2. Convery RP, Grainger AJ, Bhatnagar NK, Scott D, Bourke SJ. Lung abscess complicating chondromas in Carney's syndrome. *Eur Resp J* 1998; 11: 1409-1411.
3. Carney JA. The triad of gastric epithelioid leiomyosarcoma, pulmonary chondroma, and functioning extra-adrenal paraganglioma: a five-year review. *Medicine (Baltimore)* 1983; 62: 159-169.
4. Margulies KB, Sheps SG. Subspecialty clinics: hypertension Carney's triad: guidelines for management. *Mayo Clin Proc* 1988; 63: 496-502.
5. Kiryu T, Kawaguchi S, Matsui E, Hoshi H, Kokubo M, Shimokawa K. Multiple chondromatous hamartomas of the lung: a case report and review of the literature with special reference to Carney syndrome. *Cancer* 1999; 85: 2557-2561.
6. Scopsi L, Collini P, Muscolino G. A new observation of the carney's triad with long follow-up period and additional tumors. *Cancer Detect Prev* 1999; 23: 435-443.
7. Sans N, Durand G, Giron J, Fajadet P, Senac J. Carney's triad: update and report of one case. *J Radiol* 2000; 81: 39-42.

Caroli disease

Synonym: Caroli syndrome

Mode of inheritance: AD?/multifactorial/AR?

OMIM number: 600643

Tumour features:

intrahepatic cholangiocarcinoma

Non-tumour features:

cystic dilatations of intrahepatic bile ducts

Comment

This disorder is characterized by congenital polycystic dilatation of the intrahepatic bile ducts [1]. It is frequently associated with autosomal recessive polycystic kidney disease and congenital hepatic fibrosis (in the latter case called Caroli syndrome [2]), suggestive of a genetic overlap/allelism. There exists a marked predisposition to the development of cholangitis and liver abscesses. The clinical course can be asymptomatic for the first 5 to 20 years. Cholangiocarcinoma in the intrahepatic cystic lesions has been reported in approximately 7% of cases [3-5].

References

1. Tsuchida Y, Sato T, Sanjo K, Etoh T, Hata K, Terawaki K, Suzuki I, Kawarasaki H, Idezuki Y, Nakagome Y, et al. Evaluation of long-term results of Caroli's disease: 21 years observation of a family with autosomal "dominant" inheritance, and review of the literature. *Hepatogastroenterology* 1995; 42: 175-181.
2. Ribeiro A, Reddy RK, Bernstein D, Jeffers L, Schiff ER. Caroli's syndrome in twin sisters. *Am J Gastroenterol* 1996; 91: 1024-1026.
3. Dayton MT, Longmire WP Jr, Tompkins RK. Caroli's disease: a premalignant condition? *Am J Surg* 1983; 145: 41-48.
4. Totkas S, Hohenberger P. Cholangiocellular carcinoma associated with segmental Caroli's disease. *Eur J Surg Oncol* 2000; 26: 520-521.
5. Takatsuki M, Uemoto S, Inomata Y, Egawa H, Kiuchi T, Hayashi M, Ueda M, Tanaka K. Living-donor liver transplantation for Caroli's disease with intrahepatic adenocarcinoma. *J Hepatobiliary Pancreat Surg* 2001; 8: 284-286.

Cerebral sarcoma, familial clustering of

Mode of inheritance: multifactorial/AR?/AD?

OMIM number: 117600

Tumour features:
brain, sarcoma of the

Comment

Gainer et al. [1] reported four cases of cerebral fibrosarcomas occurring in two families: an affected father (age at diagnosis 73 years) and daughter (at 59 years); and a family with two affected sisters (diagnosed at age 64 and 69 years).

References

1. Gainer JV Jr, Chou SM, Chadduck WM. Familial cerebral sarcomas. *Arch Neurol* 1975; 32: 665-668.

Cerumen type

Mode of inheritance: AD

OMIM number: 117800

Tumour features (possible):
breast cancer

Non-tumour features:
ear wax, wet (as opposed to the dry brittle type)

Comment

Different cerumen types exist [1]. Studies of mainly the Japanese population have demonstrated two types of ear wax inheriting as an autosomal dominant trait: wet, sticky ear wax, or dry, brittle ear wax. A positive association between wet ear wax and breast cancer has been suggested, but data are presently inconclusive [2-5].

References

1. Roeser RJ, Ballachanda BB. Physiology, pathophysiology, and anthropology/epidemiology of human ear canal secretions. *J Am Acad Audiol* 1997; 8: 391-400.
2. Petrakis NL. Genetic cerumen type, breast secretory activity, and breast cancer epidemiology. In: *Genetics of Human Cancer*. Mulvihill JJ, Miller RW, Fraumeni JF (eds). Raven Press, New York 1977; 297-299.
3. Petrakis NL. Cerumen genetics and human breast cancer. *Science* 1971; 173: 347-349.
4. Ing R, Petrakis NL, Ho HC. Evidence against association between wet cerumen and breast cancer. *Lancet* 1973; 1: 41.
5. Petrakis NL, King EB, Lee M, Miike R. Cerumen phenotype and proliferative epithelium in breast fluids of U.S.-born vs. immigrant Asian women: a possible genetic-environmental interaction. *Breast Cancer Res Treat* 1990; 16: 279-285.

Cervical cancer, familial clustering of

Mode of inheritance: multifactorial

Genes: various low penetrant gene mutations have been reported, we do not list them separately here

Tumour features:
cervical cancer
ovarian cancer (i.e. epithelial origin)

Tumour features (possible):
anal cancer
hepatocellular cancer
lung/bronchial cancer
lymphoma, malignant (non-Hodgkin's and/or Hodgkin's)
oral cancer
rectal cancer
skin cancer
urinary bladder cancer

Comment

Familial clustering of cervical cancer has been reported [1-4]. An estimated 15% of patients with this tumour have at least one affected first-degree relative [1]. It has been calculated that having a first-degree relative with cervical cancer is associated with a RR of 3 of developing squamous cell cancer of the cervix, a RR of 10 of developing adenosquamous cancer at this site and no increased risk of developing cervical adenocarcinoma [1]. No other studies have confirmed these detailed findings so far. Data from the Swedish Family-Cancer Database showed a cervical cancer RR of 2.0 for daughters of affected mothers [5]. In a more recent and more detailed analysis the following figures were reported [6]: daughters of mothers with in situ cancer had a RR of 1.7 of developing in situ and RR of again 1.7 of invasive cancer. Daughters of mothers with invasive cervical cancer had a RR of 1.6 of developing in situ cancer and a RR of 2.0 of developing invasive cancer. The following other cancer types in mothers increased the risk for in situ and/or invasive cervical cancer in their daughters: lung, liver, urinary bladder and oral cancer. The following cancer types in daughters increased the risk for in situ and/or invasive cervical cancer in their mothers: lymphoma, ovarian, oral, skin and anorectal cancer.

An analysis of large Mormon families did not show increased risks of cervical cancer in women with an affected sister [7]. However, an excess of cervical cancer was observed in first-degree relatives of patients with early-onset bladder cancer (RR 2.32). A family history of cancer in general was no risk factor for cervical cancer in a Yugoslavian and a Japanese cohort [8, 9]. A study of Finnish patients with borderline ovarian

tumours and their relatives demonstrated a RR of 7.8 for cervical cancer in the mothers of index cases [10]. In a Swedish twin study, the increase in risk of cervical cancer tended to be greater if monozygotic rather than dizygotic twins were affected [11].

Certain HLA haplotypes have been found in association with an increased incidence of cervical cancer or cervical intra-epithelial neoplasia in relation to HPV infections [12-20]. Possibly, some of these HLA types and other genotypes (e.g. P53, GSTT1, GSTM1 [21]) are linked to a less effective immunoresponse to human papilloma virus (HPV) infections, a major risk factor for this tumour [22, 23].

References

1. Furgyk S, Grubb R, Kullander S, Sandahl B, Wingerup L, Eydal A. Familial occurrence of cervical cancer, stages 0-IV. *Acta Obstet Gynecol Scand* 1986; 65: 223-227.
2. Brinton LA, Tashima KT, Lehman HF, Levine RS, Mallin K, Savitz DA, Stolley PD, Fraumeni JF Jr. Epidemiology of cervical cancer by cell type. *Cancer Res* 1987; 47: 1706-1711.
3. Bruinse HW, te Velde ER, de Gast BC. Human leukocyte antigen patterns in a family with cervical cancer. *Gynecol Oncol* 1981; 12: 249-252.
4. Bender S. Carcinoma in-situ of cervix in sisters. *Br Med J* 1976; 1: 502.
5. Hemminki K, Vaitinen P, Kyrrönen P. Age-specific familial risks in common cancers of the offspring. *Int J Cancer* 1998; 78: 172-175.
6. Hemminki K, Dong C, Vaitinen P. Familial risks in cervical cancer: is there a hereditary component? *Int J Cancer* 1999; 82: 775-781.
7. Cannon L, Bishop DT, Skolnick M, Hunt S, Lyon JL, Smart CR. Genetic epidemiology of prostate cancer in the Utah Mormon genealogy. *Cancer Surv* 1982; 1: 47-69.
8. Kessler II, Kulcar Z, Zimolo A, Grgurević MH, Strnad M, Goodwin BJ. Cervical cancer in Yugoslavia. II. Epidemiologic factors of possible etiologic significance. *J Natl Cancer Inst* 1974; 53: 51-60.
9. Sasagawa T, Dong Y, Saijoh K, Satake S, Tateno M, Inoue M. Human papillomavirus infection and risk determinants for squamous intraepithelial lesion and cervical cancer in Japan. *Jpn J Cancer Res* 1997; 88: 376-384.
10. Auranen A, Grénman S, Mäkinen J, Pukkala E, Sankila R, Salmi T. Borderline ovarian tumors in Finland: epidemiology and familial occurrence. *Am J Epidemiol* 1996; 144: 548-553.
11. Ahlborn A, Lichtenstein P, Malmstrom H, Feychting M, Hemminki K, Pedersen NL. Cancer in twins: genetic and nongenetic familial risk factors. *J Natl Cancer Inst* 1997; 89: 287-293.
12. Wank R, Thomssen C. High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3. *Nature* 1991; 352: 723-725.
13. Odunsi K, Terry G, Ho L, Bell J, Cuzick J, Ganesan TS. Association between HLA DQB1*03 and cervical intra-epithelial neoplasia. *Mol Med* 1995; 1: 161-171.
14. Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. *Nat Genet* 1994; 6: 157-162.
15. Sanjeevi CB, Hjelmström P, Hallmans G, Wiklund F, Lenner P, Angström T, Dillner J, Lernmark A. Different HLA-DR-DQ haplotypes are associated with cervical intraepithelial neoplasia among human papillomavirus type-16 seropositive and seronegative Swedish women. *Int J Cancer* 1996; 68: 409-414.
16. Odunsi K, Terry G, Ho L, Bell J, Cuzick J, Ganesan TS. Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. *Int J Cancer* 1996; 67: 595-602.
17. Sastre-Garau X, Loste MN, Vincent-Salomon A, Favre M, Mouret E, De la Rochefordiere A, Durand JC, Tartour E, Lepage V, Charron D. Decreased frequency of HLA-DRB1*13 alleles in Frenchwomen with HPV-positive carcinoma of the cervix. *Int J Cancer* 1996; 69: 159-164.
18. Allen M, Kalantari M, Ylitalo N, Pettersson B, Hagmar B, Scheibenpflug L, Johansson B, Petterson U, Gyllensten U. HLA DQ-DR haplotype and susceptibility to cervical carcinoma: indications of increased risk for development of cervical carcinoma in individuals infected with HPV 18. *Tissue Antigens* 1996; 48: 32-37.
19. Helland A, Olsen AO, Gjoen K, Akselsen HE, Sauer T, Magnus P, Borresen-Dale AL, Ronningen KS. An increased risk of cervical intra-epithelial neoplasia grade II-III among human papillomavirus positive patients with the HLA-DQA1*0102-DQB1*0602 haplotype: a population-based case-control study of Norwegian women. *Int J Cancer* 1998; 76: 19-24.
20. Krul EJ, Schipper RF, Schreuder GM, Fleuren GJ, Kenter GG, Melief CJ. HLA and susceptibility to cervical neoplasia. *Hum Immunol* 1999; 60: 337-342.
21. Kim JW, Lee CG, Park YG, Kim KS, Kim IK, Sohn YW, Min HK, Lee JM, Namkoong SE. Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1: relation to the incidence rate of cervical carcinoma. *Cancer* 2000; 88: 2082-2091.
22. Schiffman MH, Brinton LA. The epidemiology of cervical carcinogenesis. *Cancer* 1995; 76 (10 Suppl): 1888-1901.
23. Magnusson PK, Gyllensten UB. Cervical cancer risk: is there a genetic component? *Mol Med Today* 2000; 6: 145-148.

Chediak-Higashi syndrome

Mode of inheritance: AR

OMIM number: 214500

Genes:

LYST/CHS, mapped to 1q42.1-q42.2

Tumour features:

non-Hodgkin's lymphoma

Tumour features (possible):

ovarian sclerosing stromal tumour

Non-tumour features:

anaemia

immunodeficiency

neutropenia

oculocutaneous albinism

Comment

This disorder (CHS) is characterized by partial oculocutaneous albinism, increased susceptibility to bacterial infections due to impaired natural killer cell activity, and the presence of massive lysosomal

inclusions in all white blood cells and of giant melanosomes in melanocytes. The majority of patients develop a lymphoproliferative disorder during the accelerated phase of the disease, which was demonstrated by Argyle et al. [1] to be a NHL T-cell lymphoma. The patients generally die in early childhood due to recurrent infections, although a late-onset type has been reported. An ovarian sclerosing stromal tumour has been detected in a girl with CHS [2]. The CHS gene has been identified [3].

References

1. Argyle JC, Kjeldsberg CR, Marty J, Shigeoka AO, Hill HR. T-cell lymphoma and the Chediak-Higashi syndrome. *Blood* 1982; 60: 672-676.
2. Inoue R, Kondo N, Motoyoshi F, Hori Y, Orii T. Chediak-Higashi syndrome: report of a case with an ovarian tumor. *Clin Genet* 1991; 39: 316-318.
3. Nagle DL, Karim MA, Woolf EA, Holmgren L, Bork P, Misumi DJ, McGrail SH, Dussault BJ Jr, Perou CM, Boissy RE, Duyk GM, Spritz RA, Moore KJ. Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. *Nat Genet* 1996; 14: 307-311.

Cheilitis glandularis

Mode of inheritance: multifactorial/AD?

OMIM number: 118330

Tumour features:

lip, squamous cell cancer of the

Non-tumour features:

lips, hypertrophy of the labial mucous glands

Comment

This disorder is characterized by chronic inflammation of the labial salivary glands, resulting in swelling, eversion and hypersecretion of the affected lips (usually the lower lip) [1]. Swerlick and Cooper [2] stated that the condition is not related to hyperplasia of the labial salivary glands, but rather is the result of an unusual reaction in response to chronic irritation of the lips. A high incidence of lower lip squamous cell cancer (in whites) is found in this disorder [3]. Possibly lip eversion causes a higher sensibility/exposure to carcinogens (rather than cheilitis glandularis itself being a precancerous condition [4]) [5]. Familial cases have been reported [5, 6].

References

1. Rogers RS 3rd, Bekic M. Diseases of the lips. *Semin Cutan Med Surg* 1997; 16: 328-336.
2. Swerlick RA, Cooper PH. Cheilitis glandularis: a re-evaluation. *J Am Acad Dermatol* 1984; 10: 466-472.

3. Carrington PR, Horn TD. Cheilitis glandularis: a clinical marker for both malignancy and/or severe inflammatory disease of the oral cavity. *J Am Acad Dermatol* 2006; 54: 336-337.
4. Bålud L. Is glandular cheilitis a precancerous disease? *Hautarzt* 1965; 16: 364-367.
5. Yacobi R, Brown DA. Cheilitis glandularis: a pediatric case report. *J Am Dent Assoc* 1989; 118: 317-318.
6. Weir TW, Johnson WC. Cheilitis glandularis. *Arch Dermatol* 1971; 103: 433-437.

Chemodectoma, intra-abdominal, with cutaneous angioliomas

Mode of inheritance: AR?/AD?/multifactorial?

OMIM number: 118350

Tumour features:

cutaneous angioliomas

paraganglioma, nonchromaffin (including glomus tumour/chemodectoma)

Comment

Lee et al. [1] reported a Maori family in which a 37-year-old man presented with multiple malignant chemodectomas (para-aortic extending to the liver, and tumours in the duodenum, pancreas, lungs and skull). He also had multiple subcutaneous angioliomas of the limbs and abdominal wall. Two brothers had died before the age of 45, cause unknown. One of them was reported to have had multiple skin tumours. Another, 40-year-old brother had similar skin tumours and presented with a malignant chemodectoma involving one of the kidneys and metastases in bones and lungs.

References

1. Lee SP, Nicholson GI, Hitchcock G. Familial abdominal chemodectomas with associated cutaneous angioliomas. *Pathology* 1977; 9: 173-177.

Cherubism

Synonym: familial benign giant-cell tumour of the jaw, familial multilocular cystic disease

Mode of inheritance: AD

OMIM number: 118400

Genes:

SH3BP2, mapped to 4p16.3

Tumour features (possible):

gingival fibroma

osteosarcoma

Non-tumour features:

dental abnormalities

jaw cysts associated with multinucleated giant cells

lower face swelling
rib cysts associated with multinucleated giant cells

Comment

This benign self-limiting disorder is characterized by swelling of the lower face, associated with multiple cystic changes in the jaw and anterior end of ribs. Biopsies of these skeletal lesions show multinucleated giant cells. Onset is around the 3rd-4th year of life and it progresses until the late teens [1-3]. Some cases may behave very aggressively [4-6]. Mangion et al. reported the occurrence of an osteosarcoma in the irradiated jaw of one of their patients [7].

References

1. Peters WJ. Cherubism: a study of twenty cases from one family. *Oral Surg Oral Med Oral Pathol* 1979; 47: 307-311.
2. Hitomi G, Nishide N, Mitsui K. Cherubism: diagnostic imaging and review of the literature in Japan. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1996; 81: 623-628.
3. Friedman E, Eisenbud L. Surgical and pathological considerations in cherubism. *Int J Oral Surg* 1981; 10 (Suppl 1): 52-57.
4. Ayoub AF, el-Mofty SS. Cherubism: report of an aggressive case and review of the literature. *J Oral Maxillofac Surg* 1993; 51: 702-705.
5. Gomes MF, de Souza Setúbal Destro MF, de Freitas Banzi EC, dos Santos SH, Claro FA, de Oliveira Nogueira T. Aggressive behaviour of cherubism in a teenager: 4-years of clinical follow-up associated with radiographic and histological features. *Dentomaxillofac Radiol* 2005; 34: 313-318.
6. Wang CN, Song YL, Peng B, Lu DH, Fan MW, Li J, Ye XQ, Fan HL, Bian Z. The aggressive form of cherubism: report of two cases in unrelated families. *Br J Oral Maxillofac Surg* 2006; 44: 322-324.
7. Mangion J, Rahman N, Edkins S, Barfoot R, Nguyen T, Sigurdsson A, Townend JV, Fitzpatrick DR, Flanagan AM, Stratton MR. The gene for cherubism maps to chromosome 4p16.3. *Am J Hum Genet* 1999; 65: 151-157.

CHIME syndrome

Mode of inheritance: AR

OMIM number: 280000

Tumour features (possible):

leukaemia, acute lymphoblastic (ALL)

Non-tumour features:

brachiocephaly
cerebral atrophy
cleft palate
deafness, conductive
eye, coloboma of the
heart, congenital defect
helices, overfolding
high birth weight
hypertelorism
ichthyosiform rash

mental deficiency
nasal bridge, broad
palmoplantar hyperkeratosis
philtrum, short
seizures

Non-tumour features (possible):

polythelia (supernumerary nipples)

Comment

This is a very rare disorder characterized by colobomas of the eye, congenital heart defects, migratory ichthyosiform rash of the skin, mental retardation and ear defects (overfolding helices and conductive deafness) (CHIME). Epilepsy, neonatal macrosomia and craniofacial dysmorphisms are additional features. Schnur et al. [1] reported a girl with this disorder who developed acute lymphoblastic leukaemia.

References

1. Schnur RE, Greenbaum BH, Heymann WR, Christensen K, Buck AS, Reid CS. Acute lymphoblastic leukemia in a child with the CHIME neuroectodermal dysplasia syndrome. *Am J Med Genet* 1997; 72: 24-29.